Pharmacovigilance Risk Assessment Committee (PRAC)
Draft agenda for the meeting on 13 - 16 May 2024

Chair: Sabine Straus – Vice-Chair: Martin Huber
13 May 2024, 10:30 – 19:30, via teleconference
14 May 2024, 08:30 – 19:30, via teleconference
15 May 2024, 08:30 – 19:30, via teleconference
16 May 2024, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)
30 May 2024, 09:00 – 12:00, via teleconference

Health and safety information
In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006 Rev.1).
# Table of contents

1. **Introduction**  
   1.1. Welcome and declarations of interest of members, alternates and experts ........ 11  
   1.2. Agenda of the meeting on 13-16 May 2024 ......................................................... 11  
   1.3. Minutes of the previous meeting on 08-11 April 2024 ........................................ 11

2. **EU referral procedures for safety reasons: urgent EU procedures** 11  
   2.1. Newly triggered procedures ................................................................................. 11  
   2.2. Ongoing procedures ............................................................................................. 11  
   2.3. Procedures for finalisation .................................................................................... 11

3. **EU referral procedures for safety reasons: other EU referral procedures** 11  
   3.1. Newly triggered procedures ................................................................................. 11  
   3.2. Ongoing procedures ............................................................................................. 11  
   3.3. Procedures for finalisation .................................................................................... 12  
      3.3.1. Hydroxyprogesterone (NAP) - EMEA/H/A-31/1528 ......................................... 12  
   3.4. Re-examination procedures .................................................................................. 12  
   3.5. Others .................................................................................................................. 12

4. **Signals assessment and prioritisation** 12  
   4.1. New signals detected from EU spontaneous reporting systems and/or other sources ................................................................................................................................. 12  
      4.1.1. Adagrasib – KRAZATI (CAP) .................................................................................. 12  
      4.1.2. Eptinezumab – VYEPTI (CAP); erenumab – AIMOVIG (CAP); fremanezumab – AJOVY (CAP); galcanezumab – EMGALITY (CAP) .............................................................. 12  
      4.1.3. Erenumab – AIMOVIG (CAP) .............................................................................. 13  
   4.2. Signals follow-up and prioritisation ...................................................................... 13  
      4.2.1. Aflibercept – EYLEA (CAP) - EMEA/H/C/002392/SDA/023, YESAFILI (CAP) - EMEA/H/C/006022/SDA/002 ........................................................................................................ 13  
      4.2.2. Baricitinib – OLUMIANT (CAP) - EMEA/H/C/004085/SDA/018 ...................... 13  
      4.2.3. Clobazam (NAP) ..................................................................................................... 13  
      4.2.4. Dabrafenib – TAFINLAR (CAP) - EMEA/H/C/002604/SDA/024, FINLEE (CAP) - EMEA/H/C/005885/SDA/003; Trametinib – MEKINIST (CAP) - EMEA/H/C/002643/SDA/019, SPEXOTRAS (CAP) - EMEA/H/C/005886/SDA/002 ........................................................................ 14  
      4.2.5. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) – EMEA/H/C/005269/SDA/017; Ivacaftor – KALYDECO (CAP) - EMEA/H/C/002494/SDA/034; Lumacaftor, ivacaftor - ORKAMBI (CAP) - EMEA/H/C/003954/SDA/018; Tezacaftor, ivacaftor - SYMKEVI (CAP) - EMEA/H/C/004682/SDA/009 ............................................................................... 14  
      4.2.6. Manidipine (NAP) ..................................................................................................... 14  
      4.2.7. Propofol (NAP) ........................................................................................................ 14

4.3. **Variation procedure(s) resulting from signal evaluation** .............................. 15  
   4.3.1. Brolucizumab - BEOVU (CAP) - EMEA/H/C/004913/II/0028 ............................ 15
## 5. Risk management plans (RMPs)

### 5.1. Medicines in the pre-authorisation phase

<table>
<thead>
<tr>
<th>Medicine</th>
<th>EMA/H/C/ID</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avacincaptad pegol (CAP MAA) - EMEA/H/C/006153</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Ciclosporin (CAP MAA) - EMEA/H/C/006250</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Delgocitinib (CAP MAA) - EMEA/H/C/006109</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Elafibranor (CAP MAA) - EMEA/H/C/006231, Orphan</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Influenza vaccine (live attenuated, nasal) (CAP MAA) - EMEA/H/C/006514</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Lerglitazone - NEZGLYAL (CAP MAA) - EMEA/H/C/005757, Orphan</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>Lutetium (177Lu) chloride (CAP MAA) - EMEA/H/C/005882</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>Trastuzumab (CAP MAA) - EMEA/H/C/006252</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>Ustekinumab (CAP MAA) - EMEA/H/C/005805</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>Ustekinumab (CAP MAA) - EMEA/H/C/006544</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>Zapomeran (CAP MAA) - EMEA/H/C/006207</td>
<td></td>
<td>16</td>
</tr>
</tbody>
</table>

### 5.2. Medicines in the post-authorisation phase – PRAC-led procedures

<table>
<thead>
<tr>
<th>Medicine</th>
<th>EMA/H/C/ID</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine, valsartan - AMLODIPINE-VALSARTAN MYLAN (CAP) - EMEA/H/C/004037/II/0021</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>Colesevelam - CHOLESTAGEL (CAP) - EMEA/H/C/000512/II/0053</td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>Fluticasone furoate - AVAMYS (CAP) - EMEA/H/C/000770/II/0051/G</td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0247</td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>Infliximab - ZESSLY (CAP) - EMEA/H/C/004647/II/0033</td>
<td></td>
<td>18</td>
</tr>
<tr>
<td>Pegcetacoplan - ASPAVELI (CAP) - EMEA/H/C/005553/II/0018, Orphan</td>
<td></td>
<td>18</td>
</tr>
<tr>
<td>Prasugrel - EFIENT (CAP) - EMEA/H/C/000984/II/0037</td>
<td></td>
<td>18</td>
</tr>
<tr>
<td>Sacituzumab govitacan - TRODELVY (CAP) - EMEA/H/C/005182/II/0031</td>
<td></td>
<td>18</td>
</tr>
<tr>
<td>Telmisartan - KINZALMONO (CAP) - EMEA/H/C/000211/WS2577/0120; MICARDIS (CAP) - EMEA/H/C/000209/WS2577/0129; PRITOR (CAP) - EMEA/H/C/000210/WS2577/0133</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Telmisartan, hydrochlorothiazide - KINZALKOMB (CAP) - EMEA/H/C/000415/WS2611/0123; MICARDISPLUS (CAP) - EMEA/H/C/000413/WS2611/0130; PRITORPLUS (CAP) - EMEA/H/C/000414/WS2611/0133</td>
<td>19</td>
<td></td>
</tr>
</tbody>
</table>

### 5.3. Medicines in the post-authorisation phase – CHMP-led procedures

<table>
<thead>
<tr>
<th>Medicine</th>
<th>EMA/H/C/ID</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afamelanotide - SCENESSE (CAP) - EMEA/H/C/002548/II/0052, Orphan</td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>Aflibercept - EYLEA (CAP) - EMEA/H/C/002392/II/0090</td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/II/0022/G</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Amivantamab - RYBREVANT (CAP) - EMEA/H/C/005454/II/0013</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Apixaban - ELIQUIS (CAP) - EMEA/H/C/002148/X/0089/G</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Blinatumomab - BLINCYTO (CAP) - EMEA/H/C/003731/II/0056, Orphan</td>
<td></td>
<td>21</td>
</tr>
<tr>
<td>Brolucizumab - BEOVU (CAP) - EMEA/H/C/004913/I/0029</td>
<td></td>
<td>21</td>
</tr>
<tr>
<td>Casirivimab, imdevimab - RONAPREVE (CAP) - EMEA/H/C/005814/II/0017</td>
<td></td>
<td>22</td>
</tr>
<tr>
<td>Defatted powder of Arachis hypogaea L., semen (peanuts) - PALFORZIA (CAP) - EMEA/H/C/004917/I/0014/G</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/II/0079</td>
<td></td>
<td>22</td>
</tr>
<tr>
<td>Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/II/0083</td>
<td></td>
<td>23</td>
</tr>
</tbody>
</table>
5.3.12. Encorafenib - BRAFTOVI (CAP) - EMEA/H/C/004580/WS2538/0034; Binimetinib - MEKTOVI (CAP) - EMEA/H/C/004579/WS2538/0030 ................................................................. 23
5.3.13. Empagliflozin, metformin - SYNJARDY (CAP) - EMEA/H/C/003770/II/0078 ............... 24
5.3.14. Epcoritamab - TEPKINLY (CAP) - EMEA/H/C/005985/II/0001, Orphan ..................... 24
5.3.15. Ganaxolone - ZTALMY (CAP) - EMEA/H/C/005825/II/0005, Orphan ...................... 24
5.3.16. Glycopyrronium - SIALANAR (CAP) - EMEA/H/C/003883/II/0029 ............................ 24
5.3.17. Imlifidase - IDEFIRIX (CAP) - EMEA/H/C/004849/II/0019, Orphan .......................... 25
5.3.18. Ivacaftor, tezacaftor, elixacaftor - KAFTRIO (CAP) - EMEA/H/C/005269/WS2551/0043; Ivacaftor - KALYDECO (CAP) - EMEA/H/C/002494/WS2551/0121 .................. 25
5.3.19. Linzagolix choline - YSELTY (CAP) - EMEA/H/C/005442/II/0013 ............................. 26
5.3.20. Lisocabtagene maraleucel - BREYANZI (CAP) - EMEA/H/C/004731/II/0036/G ........... 26
5.3.21. Lumacaftor, ivacaftor - ORKAMBI (CAP) - EMEA/H/C/003954/II/0088 ................. 26
5.3.22. Niraparib, abiraterone acetate - AKEEGA (CAP) - EMEA/H/C/005932/II/0003 ........... 27
5.3.23. Ozanimod - ZEPOSIA (CAP) - EMEA/H/C/004835/II/0023 ...................................... 27
5.3.24. Peginterferon alfa-2a - PEGASYS (CAP) - EMEA/H/C/000395/II/0119/G ................. 27
5.3.25. Pretomanid - DOVPRELA (CAP) - EMEA/H/C/005167/II/0019/G, Orphan ............... 28
5.3.26. Rilpivirine - EDURANT (CAP) - EMEA/H/C/002264/X/0042/G ................................. 28
5.3.27. Smallpox vaccine (live modified vaccinia virus Ankara) - IMVANEX (CAP) - EMEA/H/C/002596/II/0100 ................................................................. 28
5.3.28. Teclistamab - TECVAYLI (CAP) - EMEA/H/C/005865/II/0012 ............................... 29
5.3.29. Tislelizumab - TEVIMBRA (CAP) - EMEA/H/C/005919/II/0006 ............................ 29
5.3.30. Tislelizumab - TEVIMBRA (CAP) - EMEA/H/C/005919/II/0008 ............................ 30
5.3.31. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/II/0052 ................................. 30

6. Periodic safety update reports (PSURs) 31

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only ................................................................. 31

6.1.1. Abaloparatide - ELADYNOS (CAP) - PSUSA/00011029/202310 .................. 31
6.1.2. Acalabrutinib - CALQUENCE (CAP) - PSUSA/00010887/202310 (with RMP) .... 31
6.1.3. Afatinib - GIOTRIF (CAP) - PSUSA/00010054/202309 ................................. 31
6.1.4. Andexanet alfa - ONDEXXYA (CAP) - PSUSA/00010764/202310 ................ 31
6.1.5. Arsenic trioxide - TRISENOX (CAP) - PSUSA/00000235/202309 ...................... 31
6.1.6. Asciminib - SCEMBLIX (CAP) - PSUSA/00011008/202310 .................... 32
6.1.7. Axicabtagene ciloleucel - YESCARTA (CAP) - PSUSA/00010703/202310 .......... 32
6.1.8. Aztrenonam - CAYSTON (CAP) - PSUSA/00000283/202309 .................. 32
6.1.9. Bexarotene - TARGRETIN (CAP) - PSUSA/00000404/202309 ................. 32
6.1.10. Brolucizumab - BEOVU (CAP) - PSUSA/00010829/202310 .................. 32
6.1.11. Bupivacaine - EXPAREL LIPOSOMAL (CAP) - PSUSA/00010889/202310 .... 32
6.1.12. Cetuximab - ERBITUX (CAP) - PSUSA/00000635/202309 .................. 33
6.1.13. Chenodeoxycholic acid - CHENODEOXYCHOLIC ACID LEADIANT (CAP) - PSUSA/00010590/202310


6.1.15. Coronavirus (COVID-19) vaccine (recombinant protein receptor binding domain fusion heterodimer) - BIMERVAX (CAP) - PSUSA/00011045/202309

6.1.16. Dapagliflozin - EDISTRIDE (CAP); FORXIGA (CAP) - PSUSA/00010029/202310

6.1.17. Delamanid - DELTYBA (CAP) - PSUSA/00010213/202310

6.1.18. Denosumab - XGEVA (CAP) - PSUSA/00009119/202309

6.1.19. Dexamethasone - NEOFORDEX (CAP) - PSUSA/00010480/202309

6.1.20. Dostarlimab - JEMPERLI (CAP) - PSUSA/00010931/202310

6.1.21. Eculizumab - BEKEMV (CAP); EPSYQLI (CAP); SOLIRIS (CAP) - PSUSA/00011198/202310

6.1.22. Edoxaban - LIXIANA (CAP); ROTEAS (CAP) - PSUSA/00010387/202310

6.1.23. Etravirine - INTELENCE (CAP) - PSUSA/00001335/202309

6.1.24. Futibatinib - LYTGOBI (CAP) - PSUSA/00000068/202309

6.1.25. Herpes zoster vaccine (recombinant, adjuvanted) - SHINGRIX (CAP) - PSUSA/00010678/202310


6.1.27. Indacaterol, glycopyrronium bromide - ULTIBRO BREEZHALER (CAP); ULUNAR BREEZHALER (CAP); XOTERNA BREEZHALER (CAP) - PSUSA/00010105/202309

6.1.28. Insulin aspart - FIASP (CAP); INSULIN ASPART SANOFI (CAP); KIRSTY (CAP); NOVOMIX (CAP); NOVORAPID (CAP); TRUVELOG MIX 30 (SRD) (CAP) - PSUSA/00001749/202309

6.1.29. Insulin degludec – TRESIBA; insulin degludec, insulin aspart - RYZODEG (CAP); (CAP) - PSUSA/00010036/202309

6.1.30. Insulin human - INSUMAN (CAP) - PSUSA/00010107/202309

6.1.31. Ivacaftor, tezacaftor, exelacaftor - KAFTRIO (CAP) - PSUSA/00010868/202310

6.1.32. Lasmiditan - RAYVOW (CAP) - PSUSA/00011011/202310

6.1.33. Loncastuximab tesirine - ZYNLONTA (CAP) - PSUSA/00011027/202310

6.1.34. Mavacamten - CAMZYOS (CAP) - PSUSA/00000074/202310

6.1.35. Nintedanib - OFEV (CAP) - PSUSA/00010319/202310

6.1.36. Niraparib, abiraterone acetate - AKEEGA (CAP) - PSUSA/00011051/202310

6.1.37. Nirsevimab - BEYFORTUS (CAP) - PSUSA/00011026/202310

6.1.38. Parathyroid hormone - NATPAR (CAP) - PSUSA/00010591/202310

6.1.39. Pemigatinib - PEMAZYRE (CAP) - PSUSA/00010923/202310

6.1.40. Pitolisant - OZAWADE (CAP); WAKIX (CAP) - PSUSA/00010490/202309

6.1.41. Potassium citrate, potassium hydrogen carbonate - SIBNAYAL (CAP) - PSUSA/00010932/202310

6.1.42. Regorafenib - STIVARGA (CAP) - PSUSA/00010133/202309

6.1.43. Recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E - AREXVY (CAP) - PSUSA/00000031/202311

6.1.44. Selumetinib - KOSELUGO (CAP) - PSUSA/00010936/202310

6.1.45. Sirolimus - RAPAMUNE (CAP) - PSUSA/00002710/202309

6.1.46. Somatrogan - NGENLA (CAP) - PSUSA/00010982/202310
6.1.47. Sulfur hexafluoride - SONOVUE (CAP) - PSUSA/00002822/202309 ........................................ 39
6.1.48. Talazoparib - TALZENNA (CAP) - PSUSA/00010781/202310.................................................. 39
6.1.49. Talimogene laherparepvec - IMLYGIC (CAP) - PSUSA/00010459/202310 .............................. 40
6.1.50. Toremifene - FARESTON (CAP) - PSUSA/00002999/202309 ................................................... 40
6.1.51. Tremelimumab - IMJUDO (CAP) - PSUSA/00011038/202310 .............................................. 40
6.1.52. Tucatinib - TUKYSA (CAP) - PSUSA/00010918/202310 ............................................................ 40
6.1.53. Volanesorsen - WAYLIVRA (CAP) - PSUSA/00010762/202311 ............................................ 40
6.1.54. Zoonotic influenza vaccine (H5N1) - FOCLIVIA (CAP); prepandemic influenza vaccine (H5N1) - AFLUNOV (CAP); ZOONOTIC INFLUENZA VACCINE SEQIRUS (CAP) - PSUSA/00010008/202310 ............................................ 40

6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs) .............................................. 41
6.2.1. Buprenorphine - BUVIDAL (CAP); NAP - PSUSA/00000459/202309 .................................. 41
6.2.2. Buprenorphine, naloxone - SUBOXONE (CAP); ZUBSOLV (CAP); NAP - PSUSA/00021113/202309 .......................................................... 41
6.2.3. Iloprost - VENTAVIS (CAP); NAP - PSUSA/00001724/202309 ...................................................... 41
6.2.4. Leflunomide - ARAVA (CAP); LEFLUNOMIDE MEDAC (CAP); LEFLUNOMIDE ZENTIVA (CAP); NAP - PSUSA/00001837/202309 ...................................................... 41
6.2.5. Melatonin - CIRCADIN (CAP); MELATONIN NEURIM (CAP); SLENYTO (CAP); NAP - PSUSA/0001963/202309 ................................................................. 42
6.2.6. Memantine - AXURA (CAP); EBIXA (CAP); MEMANTINE MERZ (CAP); NAP - PSUSA/0001967/202309 ................................................................. 42
6.2.7. Posaconazole - NOXAFIL (CAP); NAP - PSUSA/00002480/202310 ........................................ 42
6.2.8. Sodium oxybate - XYREM (CAP); NAP - PSUSA/00010612/202310 ........................................ 42
6.2.9. Teriflunomide - AUBAGIO (CAP); TERIFLUNOMIDE ACCORD (CAP); TERIFLUNOMIDE MYLAN (CAP); NAP - PSUSA/00010135/202309 ........................................ 42
6.2.10. Vigabatrin - KIGABEQ (CAP); NAP - PSUSA/00003112/202309 ................................................ 43

6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only ........................................................................................................ 43
6.3.1. Acetylcysteine (NAP) - PSUSA/00000034/202309 ................................................................. 43
6.3.2. Acitretin (NAP) - PSUSA/00000051/202310 ................................................................. 43
6.3.3. Adapalene, benzoyl peroxide (NAP) - PSUSA/00000059/202309 ........................................ 43
6.3.4. Baclofen (NAP) - PSUSA/00000294/202309 ................................................................. 43
6.3.5. Calcium carbonate, famotidine, magnesium hydroxide (NAP) - PSUSA/00001351/202309 44
6.3.6. Desflurane (NAP) - PSUSA/00000958/202309 ................................................................. 44
6.3.7. Diclofenac (NAP) - PSUSA/00010342/202309 ................................................................. 44
6.3.8. Felodipine, ramipril (NAP) - PSUSA/00001358/202309 ....................................................... 44
6.3.9. Human von Willebrand factor (NAP) - PSUSA/00001642/202309 ........................................ 44
6.3.10. Levofloxacin (NAP) - PSUSA/00001076/202310 ................................................................. 44
6.3.11. Levofloxacin (NAP) - PSUSA/00001076/202310 ................................................................. 45
6.3.12. Prulifloxacin (NAP) - PSUSA/00002569/202309 ................................................................. 45
6.3.13. Rubidium (82Rb) chloride (NAP) - PSUSA/00010806/202310 ............................................ 45

6.4. Follow-up to PSUR/PSUSA procedures ........................................................................ 45
6.4.1. Tenofovir disoproxil - VIREAD (CAP) - EMEA/H/C/000419/LEG 279 ................................... 45
6.5. Variation procedure(s) resulting from PSUSA evaluation ........................................... 46
   6.5.1. Dabrafenib - FINLEE (CAP) - EMEA/H/C/005885/WS2671/0005; Trametinib - SPEXOTRAS (CAP) - EMEA/H/C/005886/WS2671/0004; Dabrafenib - TAFINLAR (CAP) - EMEA/H/C/002604/WS2671/0067 ......................................................... 46
   6.5.2. Ioflupane (123I) - DATSCAN (CAP) - EMEA/H/C/000266/II/0067 ................................. 46
   6.5.3. Mitotane - LYSODREN (CAP) - EMEA/H/C/000521/II/0030 ........................................ 46
   6.5.4. Naltrexone hydrochloride, Bupropion hydrochloride - MYSIMBA (CAP) - EMEA/H/C/003687/II/0063 .......................................................... 46
   6.5.5. Rituximab - MABTHERA (CAP) - EMEA/H/C/000165/II/0201/G ............................... 47
6.6. Expedited summary safety reviews ............................................................................. 47
7. Post-authorisation safety studies (PASS) ........................................................................ 47
   7.1. Protocols of PASS imposed in the marketing authorisation(s) ..................................... 47
      7.1.1. Axicabtagene ciloleucel (CAP) - YESCARTA – EMEA/H/C/PSA/S/0102.4 ...................... 47
      7.1.2. Evinacumab - EVKEEZA (CAP) – EMEA/H/C/PSA/S/0112 ........................................ 48
      7.1.3. Methylphenidate hydrochloride (NAP) – EMEA/H/N/PSA/S/0113 ........................... 48
      7.1.4. Pegzilarginase - LOARGYS (CAP) – EMEA/H/C/PSP/S/0105 ...................................... 48
      7.1.5. Valproate (CAP) – EMEA/H/N/PSP/J/0074.9 ................................................................. 48
   7.2. Protocols of PASS non-imposed in the marketing authorisation(s) ............................ 49
      7.2.1. Abaloparatide - ELADYNOS (CAP) - EMEA/H/C/005928/MEA 001.2 ...................... 49
      7.2.2. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/MEA 007.17 .................... 49
      7.2.3. Atogepant - AQUIPTA (CAP) - EMEA/H/C/005871/MEA 003 .................................. 49
      7.2.4. Atogepant - AQUIPTA (CAP) - EMEA/H/C/005871/MEA 004 .................................. 50
      7.2.5. Dabigatran etexilate - PRADAXA (CAP) - EMEA/H/C/000829/MEA 051.2 .......... 50
      7.2.6. Glofitamab - COLUMVI (CAP) - EMEA/H/C/005751/MEA 004 .............................. 50
      7.2.7. Neratinib - NERLYNX (CAP) - EMEA/H/C/004030/MEA 003.3 ............................... 50
      7.2.8. Niraparib, Abiraterone acetate - AKEEGA (CAP) - EMEA/H/C/005932/MEA 001.2 ... 51
      7.2.9. Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/MEA 010.3 ......................... 51
      7.2.10. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.10 ......... 51
      7.2.11. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.8 ............... 51
      7.2.12. Ruxolitinib - OPZELURA (CAP) - EMEA/H/C/005843/MEA 001.1 ............... 51
      7.2.13. Somapacitan - SOGROYA (CAP) - EMEA/H/C/005030/MEA 005.1 ............. 52
      7.2.14. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 025.3 ...................... 52
   7.3. Results of PASS imposed in the marketing authorisation(s) ...................................... 52
      7.3.1. Levofloxacin – QUINSAIR (CAP) - EMEA/H/C/PSR/S/0046 ................................. 52
   7.4. Results of PASS non-imposed in the marketing authorisation(s) ............................... 53
      7.4.1. Dolutegravir, Lamivudine - DOVATO (CAP) - EMEA/H/C/004909/WS2620/0047; Dolutegravir, Rilpivirine - JULUCA (CAP) - EMEA/H/C/004427/WS2620/0056; Dolutegravir - TIVICAY (CAP) - EMEA/H/C/002753/WS2620/0092; Dolutegravir, Abacavir, Lamivudine - TRIUMEQ (CAP) - EMEA/H/C/002754/WS2620/0118 ........................................................................................................................................ 53
7.4.2. Epoetin alfa - ABSEAMED (CAP) - EMEA/H/C/000727/WS2615/0108; Epoetin alfa - BINOCRIT (CAP) - EMEA/H/C/000725/WS2615/0108; Epoetin alfa - EPOETIN ALFA HEXAL (CAP) - EMEA/H/C/000726/WS2615/0108

7.4.3. Guanfacine - INTUNIV (CAP) - EMEA/H/C/003759/II/0033/G

7.4.4. Human normal immunoglobulin - HYQVIA (CAP) - EMEA/H/C/002491/II/0096

7.4.5. Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0043

7.4.6. Piperaquine tetraphosphate, arteminol - EURARTESIM (CAP) - EMEA/H/C/001199/II/0040/G

7.5. **Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation**

7.5.1. Abatacept - ORENCIA (CAP) - EMEA/H/C/000701/MEA 048.12

7.5.2. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/ANX 009.6

7.5.3. Chenodeoxycholic acid - CHENODEOXYCHOLIC ACID LEADIANT (CAP) - EMEA/H/C/004061/SOB 003.2

7.5.4. Cinacalcet - MIMPARA (CAP) - EMEA/H/C/000570/MEA 035.9

7.5.5. Damoctocog alfa pegol - JIVI (CAP) - EMEA/H/C/004054/ANX 001.3

7.5.6. Erenumab - AIMOVIG (CAP) - EMEA/H/C/004447/MEA 001.3

7.5.7. Lenvatinib - LENVIMA (CAP) - EMEA/H/C/003727/MEA 014.7

7.5.8. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 054.2

7.6. **Others**

7.7. **New Scientific Advice**

7.8. **Ongoing Scientific Advice**

7.9. **Final Scientific Advice (Reports and Scientific Advice letters)**

8. **Renewals of the marketing authorisation, conditional renewal and annual reassessments**

8.1. **Annual reassessments of the marketing authorisation**

8.1.1. Glucarpidase - VORAXAZE (CAP) - EMEA/H/C/005467/S/0025 (without RMP)


8.1.3. Susoctocog alfa - OBIZUR (CAP) - EMEA/H/C/002792/S/0056 (without RMP)

8.1.4. Tablecleucel - EBVALLO (CAP) - EMEA/H/C/004577/S/0008 (without RMP)

8.1.5. Tagraxofusp - ELZONRIS (CAP) - EMEA/H/C/005031/S/0025 (without RMP)

8.1.6. Tecovirimat - TECOVIRIMAT SIGA (CAP) - EMEA/H/C/005248/S/0010 (without RMP)

8.2. **Conditional renewals of the marketing authorisation**

8.2.1. Avapritinib - AYVAKYT (CAP) - EMEA/H/C/005208/R/0034 (without RMP)

8.2.2. Eporcitamab - TEPKINLY (CAP) - EMEA/H/C/005985/R/0004 (without RMP)

8.2.3. Imlifidase - IDEFIRIX (CAP) - EMEA/H/C/004849/R/0020 (without RMP)

8.2.4. Larotrectinib - VITRAKVI (CAP) - EMEA/H/C/004919/R/0035 (without RMP)

8.2.5. Tafasitamab - MINJUVI (CAP) - EMEA/H/C/005436/R/0015 (without RMP)

8.2.6. Valoctocogene roxaparvovec - ROCTAVIAN (CAP) - EMEA/H/C/005830/R/0011 (with RMP)

8.3. **Renewals of the marketing authorisation**

8.3.1. Arsenic trioxide - ARSENIC TRIOXIDE ACCORD (CAP) - EMEA/H/C/005175/R/0009 (without RMP)
8.3.2. Bortezomib - BORTEZOMIB FRESENIUS KABI (CAP) - EMEA/H/C/005074/R/0010 (without RMP) ................................................................. 60
8.3.3. Cannabidiol - EPIDYOLEX (CAP) - EMEA/H/C/004675/R/0031 (with RMP) ...................... 60
8.3.4. Deferasirox - DEFERASIROX MYLAN (CAP) - EMEA/H/C/005014/R/0013 (without RMP) .... 60
8.3.5. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/R/0051 (without RMP) ................. 60

9. **Product related pharmacovigilance inspections** 61

9.1. List of planned pharmacovigilance inspections ................................................................. 61
9.2. Ongoing or concluded pharmacovigilance inspections .................................................. 61
9.3. Others .................................................................................................................................. 61

10. **Other safety issues for discussion requested by the CHMP or the EMA** 61

10.1. Safety related variations of the marketing authorisation ............................................. 61
10.2. Timing and message content in relation to Member States’ safety announcements .... 61
10.3. Other requests .................................................................................................................. 61
10.4. Scientific Advice ............................................................................................................ 61

11. **Other safety issues for discussion requested by the Member States** 61

11.1. Safety related variations of the marketing authorisation ............................................. 61
11.2. Other requests .................................................................................................................. 62

12. **Organisational, regulatory and methodological matters** 62

12.1. Mandate and organisation of the PRAC ....................................................................... 62
12.1.1. PRAC membership ..................................................................................................... 62
12.1.2. Vote by proxy ............................................................................................................. 62
12.1.3. PRAC working group - Best practice guide on using PRAC plenary time efficiently and effectively – update on the implementation of quantitative goals – Q2 2023 ...................... 62
12.2. Coordination with EMA Scientific Committees or CMDh-v ........................................ 62
12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ............ 62
12.4. Cooperation within the EU regulatory network ............................................................. 62
12.4.1. Health threats and EMA Emergency Task Force (ETF) activities - update .................. 62
12.5. Cooperation with International Regulators ................................................................. 62
12.5.1. International Council for Harmonisation (ICH) M14 Guideline on 'General principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines' ......................................................................................... 62
12.6. Contacts of PRAC with external parties and interaction with the Interested Parties to the Committee ...................................................... 63
12.7. PRAC work plan ............................................................................................................. 63
12.8. Planning and reporting .................................................................................................... 63
12.8.1. EU Pharmacovigilance system - quarterly workload measures and performance indicators – Q1 2024 and predictions ........................................ 63
12.8.2. PRAC workload statistics – Q1 2024 ........................................................................ 63
12.9. Pharmacovigilance audits and inspections ........................................................... 63
   12.9.1. Pharmacovigilance systems and their quality systems ........................................ 63
   12.9.2. Pharmacovigilance inspections .......................................................................... 63
   12.9.3. Pharmacovigilance audits ................................................................................... 63
12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list ...... 63
   12.10.1. Periodic safety update reports .......................................................................... 63
   12.10.2. Granularity and Periodicity Advisory Group (GPAG) ......................................... 63
   12.10.3. PSURs repository .............................................................................................. 64
   12.10.4. Union reference date list – consultation on the draft list ..................................... 64
12.11. Signal management ........................................................................................... 64
12.12. Adverse drug reactions reporting and additional reporting .............................. 64
   12.12.1. Management and reporting of adverse reactions to medicinal products ............ 64
   12.12.2. Additional monitoring ...................................................................................... 64
   12.12.3. List of products under additional monitoring – consultation on the draft list ......... 64
12.13. EudraVigilance database .................................................................................... 64
   12.13.1. Activities related to the confirmation of full functionality .................................... 64
12.14. Risk management plans and effectiveness of risk minimisations ....................... 64
   12.14.1. Risk management systems ............................................................................... 64
   12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations 65
12.15. Post-authorisation safety studies (PASS) ......................................................... 65
   12.15.1. Post-authorisation Safety Studies – imposed PASS ............................................. 65
   12.15.2. Post-authorisation Safety Studies – non-imposed PASS .................................... 65
12.16. Community procedures .................................................................................... 65
   12.16.1. Referral procedures for safety reasons ................................................................ 65
12.17. Renewals, conditional renewals, annual reassessments ................................. 65
12.18. Risk communication and transparency ............................................................. 65
   12.18.1. Public participation in pharmacovigilance .......................................................... 65
   12.18.2. Safety communication ....................................................................................... 65
12.19. Continuous pharmacovigilance ......................................................................... 65
   12.19.1. Incident management ......................................................................................... 65
12.20. Impact of pharmacovigilance activities ............................................................. 66
12.21. Others ................................................................................................................ 66
   12.21.1. Antiepileptic drugs and pregnancy ...................................................................... 66

13. Any other business 66
14. Explanatory notes 66
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 13-16 May 2024. See May 2024 minutes (to be published post June 2024 PRAC meeting).

1.2. **Agenda of the meeting on 13-16 May 2024**

**Action:** For adoption

1.3. **Minutes of the previous meeting on 08-11 April 2024**

**Action:** For adoption

2. **EU referral procedures for safety reasons: urgent EU procedures**

2.1. **Newly triggered procedures**

None

2.2. **Ongoing procedures**

None

2.3. **Procedures for finalisation**

None

3. **EU referral procedures for safety reasons: other EU referral procedures**

3.1. **Newly triggered procedures**

None

3.2. **Ongoing procedures**

None
3.3. **Procedures for finalisation**

3.3.1. **Hydroxyprogesterone (NAP) - EMEA/H/A-31/1528**

- **Applicant(s):** various
- **PRAC Rapporteur:** Amelia Cupelli; **PRAC Co-rapporteur:** Nathalie Gault
- **Scope:** Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data
- **Action:** For adoption of a recommendation to CMDh

3.4. **Re-examination procedures**

- **None**

3.5. **Others**

- **None**

4. **Signals assessment and prioritisation**

4.1. **New signals detected from EU spontaneous reporting systems and/or other sources**

4.1.1. **Adagrasib – KRAZATI (CAP)**

- **Applicant:** Bristol-Myers Squibb Pharma EEIG
- **PRAC Rapporteur:** Kimmo Jaakkola
- **Scope:** Signal of febrile neutropenia
- **Action:** For adoption of PRAC recommendation
- **EPITT 20080 – New Signal**
- **Lead Member State(s):** FI

4.1.2. **Eptinezumab – VYEPTI (CAP); erenumab – AIMOVIG (CAP); fremanezumab – AJOVY (CAP); galcanezumab – EMGALITY (CAP)**

- **Applicant(s):** H. Lundbeck A/S (Vyepti), Novartis Europharm Limited (Aimovig), TEVA GmbH (Ajovy), Eli Lilly Nederland B.V. (Emgality)
- **PRAC Rapporteur:** to be appointed

1 Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
2 Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required
Scope: Signal of insomnia

**Action:** For adoption of PRAC recommendation

EPITT 20077 – New signal

Lead Member State(s): FI, NL

### 4.1.3. Erenumab – AIMOVIG (CAP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Kirsti Villikka

Scope: Signal of hypertension

**Action:** For adoption of PRAC recommendation

EPITT 20081 – New signal

Lead Member State(s): FI

### 4.2. Signals follow-up and prioritisation

#### 4.2.1. Aflibercept – EYLEA (CAP) - EMEA/H/C/002392/SDA/023, YESAFILI (CAP) - EMEA/H/C/006022/SDA/002

Applicant(s): Bayer AG (Eylea), Biosimilar Collaborations Ireland Limited (Yesafili)

PRAC Rapporteur: Nathalie Gault

Scope: Signal of nephropathy toxic after intravitreal administration

**Action:** For adoption of PRAC recommendation

EPITT 20024 – Follow-up to January 2024

#### 4.2.2. Baricitinib – OLUMIANT (CAP) - EMEA/H/C/004085/SDA/018

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Signal of hypoglycaemia in diabetic patients

**Action:** For adoption of PRAC recommendation

EPITT 20038 – Follow-up to January 2024

#### 4.2.3. Clobazam (NAP)

Applicant(s): various

PRAC Rapporteur: Kimmo Jaakkola

Scope: Signal of drug rash with eosinophilia and systemic symptoms (DRESS)

**Action:** For adoption of PRAC recommendation
4.2.4. Dabrafenib – TAFINLAR (CAP) - EMEA/H/C/002604/SDA/024, FINLEE (CAP) - EMEA/H/C/005885/SDA/003; Trametinib – MEKINIST (CAP) - EMEA/H/C/002643/SDA/019, SPEXOTRAS (CAP) - EMEA/H/C/005886/SDA/002

Applicant: Novartis Europharm Limited
PRAC Rapporteur: David Olsen
Scope: Signal of acute febrile neutrophilic dermatosis
Action: For adoption of PRAC recommendation

EPITT 20022 – Follow-up to January 2024

4.2.5. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) – EMEA/H/C/005269/SDA/017; Ivacaftor - KALYDECO (CAP) - EMEA/H/C/002494/SDA/034; Lumacaftor, ivacaftor - ORKAMBI (CAP) - EMEA/H/C/003954/SDA/018; Tezacaftor, ivacaftor - SYMKEVI (CAP) - EMEA/H/C/004682/SDA/009

Applicant: Vertex Pharmaceuticals (Ireland) Limited
PRAC Rapporteur: Martin Huber
Scope: Signal of intracranial pressure increased
Action: For adoption of PRAC recommendation

EPITT 20000 – Follow-up to December 2023

4.2.6. Manidipine (NAP)

Applicant(s): various
PRAC Rapporteur: Amelia Cupelli
Scope: Signal of ascites
Action: For adoption of PRAC recommendation

EPITT 20026 – Follow-up to January 2024

4.2.7. Propofol (NAP)

Applicant(s): various
PRAC Rapporteur: Karen Pernille Harg
Scope: Signal of hepatic failure
Action: For adoption of PRAC recommendation

EPITT 20020 – Follow-up to January 2024

3 Held 27-30 November 2023
4.3. Variation procedure(s) resulting from signal evaluation

4.3.1. Brolucizumab - BEOVU (CAP) - EMEA/H/C/004913/II/0028

Applicant: Novartis Europharm Limited
PRAC Rapporteur: Gabriele Maurer
Scope: Update of section 4.8 of the SmPC in order to add ‘scleritis’ to the list of adverse drug reactions (ADRs) with frequency ‘not known’, following the recommendation by PRAC in the outcome for the signal assessment of scleritis. The package leaflet is updated accordingly
Action: For adoption of PRAC Assessment Report

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Avacincaptad pegol (CAP MAA) - EMEA/H/C/006153
Scope (pre D-180 phase): Treatment of adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Ciclosporin (CAP MAA) - EMEA/H/C/006250
Scope (pre D-180 phase): Treatment of dry eye disease in adult patients
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. Delgocitinib (CAP MAA) - EMEA/H/C/006109
Scope (pre D-180 phase): Treatment of moderate to severe chronic hand eczema (CHE)
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. Elafibranor (CAP MAA) - EMEA/H/C/006231, Orphan
Applicant: Ipsen Pharma
Scope (pre D-180 phase): Treatment of primary biliary cholangitis (PBC)
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.5. Influenza vaccine (live attenuated, nasal) (CAP MAA) - EMEA/H/C/006514
Scope (pre-opinion phase): Active immunisation to prevent influenza disease
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.6. Leriglitazone - NEZGLYAL (CAP MAA) - EMEA/H/C/005757, Orphan

**Applicant:** Minoryx Therapeutics S.L.

**Scope (under re-examination):** Treatment of cerebral progression and myelopathy in male patients with adrenoleukodystrophy (ALD)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.7. Lutetium (177Lu) chloride (CAP MAA) - EMEA/H/C/005882

**Scope (pre D-180 phase):** Radiolabelling of carrier molecules, which have been specifically developed for radiolabelling with this radionuclide

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.8. Trastuzumab (CAP MAA) - EMEA/H/C/006252

**Scope (pre D-180 phase):** Treatment of adult patients with HER2 positive metastatic breast cancer (MBC) and HER2 positive early breast cancer (EBC)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.9. Ustekinumab (CAP MAA) - EMEA/H/C/005805

**Scope (pre D-180 phase):** Treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease and ulcerative colitis

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.10. Ustekinumab (CAP MAA) - EMEA/H/C/006544

**Scope:** Treatment of Crohn’s disease and ulcerative colitis, moderate to severe plaque psoriasis, active and psoriatic arthritis

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.11. Zapomeran (CAP MAA) - EMEA/H/C/006207

**Scope (pre D-180 phase):** Active immunisation to prevent COVID-19

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.2. Medicines in the post-authorisation phase – PRAC-led procedures

#### 5.2.1. Amlodipine, valsartan - AMLODIPINE-VALSARTAN MYLAN (CAP) - EMEA/H/C/004037/II/0021

**Applicant:** Mylan Pharmaceuticals Limited
PRAC Rapporteur: Karin Erneholm

Scope: Submission of an updated RMP version 4.0 in order to align the safety concerns with the latest version of RMP for omlodipine/walsartan available in the public domain and to bring the RMP in line with the latest RMP template

**Action:** For adoption of PRAC Assessment Report

### 5.2.2. Colesevelam - CHOLESTAGEL (CAP) - EMEA/H/C/000512/II/0053

Applicant: CHEPLAPHARM Arzneimittel GmbH

PRAC Rapporteur: Bianca Mulder

Scope: Submission of an updated RMP version 2.0 in order to remove important identified and potential risks, as well as missing information to bring it in line with GVP module V. Additionally, epidemiological data on indication and target population, clinical data and postmarketing exposure data was updated

**Action:** For adoption of PRAC Assessment Report

### 5.2.3. Fluticasone furoate - AVAMYS (CAP) - EMEA/H/C/000770/II/0051/G

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Adam Przybylkowski

Scope: Grouped application comprising two type II variations as follows:
- C.I.11.b – Submission of an updated RMP version 12 in order to remove headache, nasal events (including: epistaxis, nasal ulceration, nasal septum perforation and other nasal events), hypersensitivity, cataract and glaucoma as important identified risks; to remove taste and smell disorders, pyrexia, systemic corticosteroids effect: adrenal suppression, Systemic corticosteroid effect: growth retardation, psychiatric effects as important potential risks and to remove use in pregnancy and lactation, off-label use (sinusitis and children < 6 years of age) as missing information.
- C.I.11.b – Submission of an updated RMP version 12 in order to remove targeted follow up questionnaires.

In addition, the MAH took this opportunity to align the RMP template with GVP Module V Revision 2

**Action:** For adoption of PRAC Assessment Report

### 5.2.4. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0247

Applicant: Janssen Biologics B.V.

PRAC Rapporteur: Mari Thorn

Scope: Submission of an updated RMP version 22.1 in order to remove reference to the immunogenicity substudy as part of protocol REMICADEPIB4002 in Part III. The MAH proposes to discontinue the Dutch portion of the immunogenicity substudy, which is part of protocol REMICADEPIB4002

**Action:** For adoption of PRAC Assessment Report
5.2.5. **Infliximab - ZESSLY (CAP) - EMEA/H/C/004647/II/0033**

Applicant: Sandoz GmbH
PRAC Rapporteur: Mari Thorn
Scope: Submission of an updated RMP version 4.0 in order to remove the UKIBD (UK) registry from the additional pharmacovigilance activities

**Action:** For adoption of PRAC Assessment Report

5.2.6. **Pegcetacoplan - ASPAVELI (CAP) - EMEA/H/C/005553/II/0018, Orphan**

Applicant: Swedish Orphan Biovitrum AB (publ)
PRAC Rapporteur: Kimmo Jaakkola
Scope: Submission of an updated RMP version 2.1 in order to revise the category 3 PASS Sobi.PEGCET-301 and Sobi.PEGCET-302

**Action:** For adoption of PRAC Assessment Report

5.2.7. **Prasugrel - EFIENT (CAP) - EMEA/H/C/000984/II/0037**

Applicant: Substipharm
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Submission of an updated RMP version 13 in order to remove of a region-specific additional risk-minimisation activity following previous PSUSA procedure (EMEA/H/C/PSUSA/00002499/202102), as well as to align content and format with new requirements according to GVP Module V Rev. 2. In addition, the MAH took the opportunity to update Annex II of the product information and to update the list of local representatives in the package leaflet

**Action:** For adoption of PRAC Assessment Report

5.2.8. **Sacituzumab govitecan - TRODELVY (CAP) - EMEA/H/C/005182/II/0031**

Applicant: Gilead Sciences Ireland UC
PRAC Rapporteur: Bianca Mulder
Scope: Submission of an updated RMP version 3.1 in order to propose the removal of some safety concerns and the extension of remaining study milestones to date for category 3 study IMMU-132-15

**Action:** For adoption of PRAC Assessment Report

5.2.9. **Telmisartan - KINZALMONO (CAP) - EMEA/H/C/000211/WS2577/0120; MICARDIS (CAP) - EMEA/H/C/000209/WS2577/0129; PRITOR (CAP) - EMEA/H/C/000210/WS2577/0133**

Applicant: Boehringer Ingelheim International GmbH
PRAC Rapporteur: Amelia Cupelli
Scope: Submission of an updated RMP version 6.1 in order to implement an overall update regarding safety concerns based on literature and post marketing data; and to adapt the RMP to the current RMP format (Rev 2.0.1), in line with GVP Module V, Revision 2

**Action:** For adoption of PRAC Assessment Report

### 5.2.10. Telmisartan, hydrochlorothiazide - KINZALKOMB (CAP) - EMEA/H/C/000415/WS2611/0123; MICARDISPLUS (CAP) - EMEA/H/C/000413/WS2611/0130; PRITORPLUS (CAP) - EMEA/H/C/000414/WS2611/0133

**Applicant:** Boehringer Ingelheim International GmbH

**PRAC Rapporteur:** Amelia Cupelli

Scope: Submission of an updated RMP version 9.1 for MicardisPlus, PritorPlus and Kinzalkomb in order to remove all important identified and potential risks from the list of safety concerns and to adapt the RMP to the current RMP format (Rev 2.0.1), in line with GVP Module V, Revision 2

**Action:** For adoption of PRAC Assessment Report

### 5.3. Medicines in the post-authorisation phase – CHMP-led procedures

#### 5.3.1. Afamelanotide - SCENESSE (CAP) - EMEA/H/C/002548/II/0052, Orphan

**Applicant:** Clinuvel Europe Limited

**PRAC Rapporteur:** Martin Huber

Scope: Update of section 4.2 of the SmPC in order to update the posology recommendations by removing the current recommendation of a maximum of four implants per year, based on a literature review and analysis of safety data. The package leaflet is updated accordingly. The RMP version 9.8 has also been submitted. In addition, the MAH took the opportunity to introduce a minor editorial change to the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.2. Aflibercept - EYLEA (CAP) - EMEA/H/C/002392/II/0090

**Applicant:** Bayer AG

**PRAC Rapporteur:** Nathalie Gault

Scope: Update of sections 4.8 and 5.1 of the SmPC in order to update safety and clinical information based on results from studies PULSAR (20968) and PHOTON (21091). PULSAR (20968) is an ongoing pivotal Phase 3 study to investigate the efficacy and safety of HD aflibercept at treatment intervals of 12 weeks and longer for indication neovascular age-related macular degeneration (nAMD). PHOTON (21091) is an ongoing pivotal phase 2/3 study to investigate the efficacy and safety of HD aflibercept at treatment intervals of 12 weeks and longer for indication diabetic macular oedema. The package leaflet is updated accordingly. The RMP version 34.1 has also been submitted. In addition, the MAH took the opportunity to implement an editorial update
in section 6.6 of the SmPC to align the text with other similar products

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.3. **Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/II/0022/G**

**Applicant:** Novartis Europharm Limited

**PRAC Rapporteur:** Bianca Mulder

**Scope:** Grouped application comprising two type II variations (C.I.4) as follows:
- Update of sections 4.2, 4.4, 4.8 of the SmPC in order to update information on prophylactic use of metformin for hyperglycaemia based on the results from study CBYL719CES01T (METALLICA). METALLICA is a phase II study aimed to evaluate the effect of prophylactic use of metformin for hyperglycaemia in HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer patients treated with alpelisib plus endocrine therapy.
- Update of section 4.8 of the SmPC in order to add 'uveitis' to the list of adverse drug reactions (ADRs) with frequency 'Not known' based on a cumulative review of the MAH safety database and literature.

The package leaflet and Annex II are updated accordingly. The RMP version 7.0 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.4. **Amivantamab - RYBREVANT (CAP) - EMEA/H/C/005454/II/0013**

**Applicant:** Janssen-Cilag International N.V.

**PRAC Rapporteur:** Gabriele Maurer

**Scope:** Extension of indication to include amivantamab in combination with lazertinib for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations (EGFRm NSCLC), based on results from study 73841937NSC3003 (MARIPOSA). This is a randomised, open-label, phase 3 study that compares the efficacy and safety of the combination of amivantamab and lazertinib (Arm A) versus osimertinib monotherapy (Arm B) and lazertinib monotherapy (Arm C) in participants with EGFRm NSCLC. The primary objective of the MARIPOSA study was to assess the efficacy of the combination of amivantamab and lazertinib (Arm A), compared with osimertinib (Arm B), as measured by PFS assessed by BICR in adult participants with EGFRm NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1, 5.2, 6.6 and 9 of the SmPC are updated. The package leaflet is updated in accordance.

Version 3.3 of the EU RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.5. **Apixaban - ELIQUIS (CAP) - EMEA/H/C/002148/X/0089/G**

**Applicant:** Bristol-Myers Squibb / Pfizer EEIG

**PRAC Rapporteur:** Bianca Mulder

**Scope:** Extension application to:
1) Introduce a new pharmaceutical form (granules in single-dose container) associated with a new strength (0.15 mg).
2) Introduce a new pharmaceutical form (coated granules in sachet) associated with 3 new strengths (0.5 mg, 1.5 mg and 2 mg);

The above two line extensions are grouped with a type II - C.1.6.a variation:
Extension of indication to include the treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age for Eliquis (all strengths), based on a pre-specified interim analysis from study CV185325; this is an open-label, multi-centre, randomised, active controlled trial to provide pharmacokinetic (PK) data and data on anti-Xa activity to support the extrapolation of efficacy to children, to evaluate safety and efficacy of apixaban in children who require anticoagulation for a venous thromboembolism; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 5.2 of the SmPCs are updated. The package leaflet and Annex II are updated in accordance. Version 21.0 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

### 5.3.6. Blinatumomab - BLINCYTO (CAP) - EMEA/H/C/003731/II/0056, Orphan

**Applicant:** Amgen Europe B.V.

**PRAC Rapporteur:** Jana Lukacisinova

**Scope:** Extension of indication to include treatment as part of consolidation therapy for the treatment of patients with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) for BLINCYTO. The proposed indication is supported by efficacy data from Studies E1910, 20120215, and AALL1331, safety data for Studies E1910, 20120215, AALL1331, MT103-202, and MT103-203, and pharmacokinetic data for studies 20120215, AALL1331, MT103-202, MT103-203, and 20190360. As a consequence, sections 4.1, 4.2, 4.8, 5.1, and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 18.0 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

### 5.3.7. Brolucizumab - BEOVU (CAP) - EMEA/H/C/004913/II/0029

**Applicant:** Novartis Europharm Limited

**PRAC Rapporteur:** Gabriele Maurer

**Scope:** Update of sections 4.2 and 5.1 of the SmPC in order to include information on maintenance treatment and to update efficacy and safety information based on final results from studies CRTH258A2303 (TALON) and CRTH258A2303E1 (TALON Extension). TALON is a 64-week, two-arm, randomised, double-masked, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration. TALON Extension is a 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6 mg in a treat-to-control regimen with maximum treatment intervals up to 20 weeks for the treatment of subjects with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study. The package leaflet is updated accordingly. The RMP version 12.0 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.8. Casirivimab, imdevimab - RONAPREVE (CAP) - EMEA/H/C/005814/II/0017

Applicant: Roche Registration GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Extension of indication to include treatment of paediatric patients from 2 to less than 12 years old, weighing at least 10kg, who do not require supplemental oxygen and who are at increased risk of progression to severe COVID-19 for Ronapreve, based on final results from study COV-2067; this was a seamless, adaptive, phase 3, randomised, double-blinded, placebo-controlled, multi-centre study to evaluate the efficacy, safety, and tolerability of casirivimab+imdevimab combination therapy in paediatric and adult outpatients with mild to moderate COVID-19. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.9. Defatted powder of Arachis hypogaea L., semen (peanuts) - PALFORZIA (CAP) - EMEA/H/C/004917/II/0014/G

Applicant: Aimmune Therapeutics Ireland Limited

PRAC Rapporteur: Kirsti Villikka

Scope: Grouped variation consisting of:

C.I.6.a: Extension of indication to include treatment of patients 1 to 3 years old for PALFORZIA, based on final results from study ARC005; this is a phase 3 randomised, double-blind, placebo-controlled Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) to evaluate the safety and efficacy of peanut powder in terms of superiority of placebo in children of 1 year to less than 4 years of age with peanut allergy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 6.5 and 8 of the SmPC are updated. The package leaflet and labelling were updated accordingly. Version 1.1 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to implement editorial changes to the SmPC and to update the list of local representatives in the package leaflet. As part of the application the MAH is requesting a 1-year extension of the market protection.

B.II.e.5.a: Introduction of a new pack-size of 16 capsules of 1 mg (Level 0) in blisters for PALFORZIA, 1 mg, oral powder in capsules for opening. Due to the lack of a suitable pack-size for the up-dosing phase for patients 1 to 3 years old, a new pack size Level 0 for the up-dosing phase will be introduced. Labelling was updated accordingly. In addition, the MAH took the opportunity to update module 3.2.P.3.1 to take out the EU importation site (editorial change)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/II/0079

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication for DUPIXENT to include treatment of adults as add-on
maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) with type 2 inflammation on triple therapy or double therapy if inhaled corticosteroids (ICS) are contraindicated, based on final results from study EFC15804 (BOREAS); this is a phase 3, randomised, double blind, placebo-controlled, multi-centre, parallel group, 52-week study to assess the efficacy, safety and tolerability of dupilumab in patients with moderate-to-severe COPD with type 2 inflammation. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 10.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11.  Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/II/0083

Applicant: Sanofi Winthrop Industrie
PRAC Rapporteur: Kimmo Jaakkola
Scope: Extension of indication to include treatment of moderate to severe chronic spontaneous urticaria (CSU) in adults and adolescents 12 years and older, who are symptomatic despite treatment with H1 antihistamines and who are intolerant to or inadequately controlled by anti-IgE therapy for Dupixent, based on the results from studies EFC16461 (CUPID) study B (pivotal) and study A (supportive); EFC16461 Study B was a 24-week, double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of dupilumab in adult and adolescent participants with CSU who remained symptomatic despite the use of H1-antihistamine and who were intolerant or incomplete responders to omalizumab and EFC16461 Study A was a 24-week, double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of dupilumab in participants with CSU who remained symptomatic despite the use of H1-antihistamine and who were naïve to omalizumab. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 11.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12.  Encorafenib - BRAFTOVI (CAP) - EMEA/H/C/004580/WS2538/0034; Binimetinib - MEKTOVI (CAP) - EMEA/H/C/004579/WS2538/0030

Applicant: Pierre Fabre Medicament
PRAC Rapporteur: Rugile Pilviniene
Scope: Extension of indication to include binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation for MEKTOVI and BRAFTOVI based on results from study PHAROS (study ARRAY-818-202) at the primary completion date; this is a phase II, open-label, multicentre, non-comparative study (interventional). As a consequence, sections 4.1, 4.4, 4.8, 5.1, 5.2, 9 and 10 of the SmPC are updated. The package leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. As part of the application, the MAH is requesting a 1-year extension of the market protection for MEKTOVI

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.13. Empagliflozin, metformin - SYNJARDY (CAP) - EMEA/H/C/003770/II/0078

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Extension of indication to include the treatment of children aged 10 years and above with type 2 diabetes for Synjardy, based on the final results from study 1218-0091 (DINAMO) - a double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 16.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the package leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.14. Epcoritamab - TEPKINLY (CAP) - EMEA/H/C/005985/II/0001, Orphan

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Monica Martinez Redondo

Scope: Extension of indication to include treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy for TEPKINLY, based on results from the indolent Non-Hodgkins Lymphoma (iNHL) expansion cohort of Study GCT3013-01, the first In human (FIH) phase 1/2 study in R/R B-NHL, with key supportive data from the Phase 1b/2 Study GCT3013-04 in Japanese subjects. Study GCT3013-01 is an ongoing global, single-arm, phase 1/2 study designed to evaluate epcoritamab as monotherapy in R/R B-NHL. As a consequence, sections 1, 3, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 6.3, 6.4, 6.5 and 6.6 of the SmPC are updated. The package leaflet and labelling are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.15. Ganaxolone - ZTALMY (CAP) - EMEA/H/C/005825/II/0005, Orphan

Applicant: Marinus Pharmaceuticals Emerald Limited

PRAC Rapporteur: Adam Przybylkowski

Scope: Update of section 4.2 of the SmPC in order to update dosing instructions in severe hepatic impairment based on data from phase I study 1042-IHF-1001. The RMP version 1.3 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.16. Glycopyrronium - SIALANAR (CAP) - EMEA/H/C/003883/II/0029

Applicant: Proveca Pharma Limited
PRAC Rapporteur: Zane Neikena

Scope: Extension of indication to include treatment of children aged from 2 years and older for SIALANAR, based on the interim results from study PRO/GLY/005. This is a retrospective analysis of real-world data from children aged under 3 years treated with glycopyrronium for severe drooling. As a consequence, sections 4.1, 4.2, and 4.4 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. As part of the application the MAH is requesting a 1-year extension of the market protection.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.17. Imlifidase - IDEFIRIX (CAP) - EMEA/H/C/004849/II/0019, Orphan

Applicant: Hansa Biopharma AB

PRAC Rapporteur: Bianca Mulder

Scope: Update of section 5.1 of the SmPC in order to include the description of the final results from post-authorisation efficacy study (PAES) study 17-HMedIdeS-14 listed as a specific obligation in the Annex II (SOB/002); this is a prospective, observational long-term follow-up study of patients treated with imlifidase (IdeS) prior to kidney transplantation. The primary objective of this trial was to evaluate graft survival in patients who have undergone kidney transplantation after imlifidase administration in earlier trials and relates to both safety and efficacy. The RMP version 1.2 has also been submitted. In addition, the MAH took the opportunity to update section E of Annex II and to implement editorial changes to sections 4.4, 4.6 and 9 of the SmPC. Furthermore, the MAH took the opportunity to bring the product information in line with the latest QRD template version 10.3

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.18. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) - EMEA/H/C/005269/WS2551/0043; Ivacaftor - KALYDECO (CAP) - EMEA/H/C/002494/WS2551/0121

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Martin Huber

Scope: Extension of the indication for Kaftrio (ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) in a combination regimen to include the treatment of patients with cystic fibrosis (CF) aged 2 years and older who do not carry any F508del mutations and have at least one ivacaftor/tezacaftor/elexacaftor-responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene based on study VX21-445-124, study VX21-445-125 and study VX22-CFD-016. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the Kaftrio SmPC are updated; sections 4.1 and 5.1 of the Kalydeco SmPC are updated. The package leaflet is updated in accordance. In addition, the MAH took this opportunity to introduce editorial changes to the product information.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.19. Linzagolix choline - YSELTY (CAP) - EMEA/H/C/005442/II/0013

Applicant: Theramex Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: Extension of indication to include treatment of endometriosis-associated pain in adult women of reproductive age for YSELTY, based on final results from studies Edelweiss 3 (18-OBE2109-003) and Edelweiss 6 (19-OBE2109-006) as well as additional supporting studies. Edelweiss 3 is a pivotal phase 3, randomised, double-blind, placebo-controlled, safety and efficacy study to evaluate linzagolix with add-back therapy as a therapy for pain associated with endometriosis, while Edelweiss 6 is an open-label extension study including patients who completed Edelweiss 3 pivotal study regardless of their previous treatment assignment and met the eligibility criteria. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. As part of the application, the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Lisocabtagene maraleucel - Breyanzi (CAP) - EMEA/H/C/004731/II/0036/G

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP

PRAC Rapporteur: Gabriele Maurer

Scope: Grouped application comprising two variations as follows:
C.I.4 – Update of sections 4.4 and 4.8 of the SmPC in order to add immune effector cell-associated neurotoxicity syndrome (ICANS) as an adverse drug reaction (ADR) based on the cumulative review of MAH safety database and literature. The package leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce editorial changes.
A.6 – To include the ATC Code L01XL08 in section 5.1 of the SmPC. RMP version 4.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.21. Lumacaftor, ivacaftor - Orkambi (CAP) - EMEA/H/C/003954/II/0088

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Eamon O’Murchu

Scope: Submission of the final report from study VX19-809-124 (Study 124), listed as a category 3 study in the RMP. This is a phase 3, open-label, rollover study to evaluate the long-term safety and tolerability of lumacaftor/ivacaftor in cystic fibrosis subjects homozygous for F508del who were 1 to <2 years of age at treatment initiation and who completed the safety follow-up (SFU) visit in Study 122 (Part B) or were lumacaftor/ivacaftor naive. The RMP version 11.5 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.22.  **Niraparib, abiraterone acetate - AKEEGA (CAP) - EMEA/H/C/005932/II/0003**

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Jan Neuhauser

Scope: Update of sections 4.8 and 5.1 of the SmPC in order to update the frequency of adverse drug reactions and to update information from MAGNITUDE study based on final results from study 6409174PCR3001 (MAGNITUDE) listed as a post-authorisation efficacy study (PAES) in the Annex II. This is a phase 3 randomised, placebo-controlled, double-blind, multicenter study which assessed the efficacy and safety of niraparib 200 mg in combination with AA 1,000 mg once daily plus prednisone or prednisolone 10 mg daily (AAP), compared with placebo plus AAP in men with mCRPC and HRR gene alterations, approximately half of whom had BRCA gene alterations and comprised the prespecified BRCA subgroup.

The Annex II and package leaflet are updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took this opportunity to update the list of local representatives in the package leaflet and to introduce editorial changes to the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23.  **Ozanimod - ZEPOSIA (CAP) - EMEA/H/C/004835/II/0023**

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Update of sections 4.4 and 5.1 of the SmPC in order to update efficacy and safety information based on the final results from study RPC01-3001, listed as a category 3 study in the RMP. This is a multi-site, open label extension trial of RPC1063 in relapsing multiple sclerosis. The study’s main objectives were to characterise the long-term safety and tolerability, and the long-term efficacy of ozanimod in patients with relapsing multiple sclerosis. The RMP version 7.0 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24.  **Peginterferon alfa-2a - PEGASYS (CAP) - EMEA/H/C/000395/II/0119/G**

Applicant: Pharmaand GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Grouped application consisting of extension of indication to include treatment of polycythaemia vera (PV) and essential thrombocytopenia (ET) for PEGASYS, based on published data of clinical studies conducted in support of the efficacy and safety of Pegasys for the treatment of ET and PV. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 10.1 of the RMP has also been submitted. Furthermore, the product information is brought in line with the latest QRD template version 10.3

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.25. Pregabalin - LYRICA (CAP) - EMEA/H/C/000546/X/0127

Applicant: Upjohn EESV
PRAC Rapporteur: Liana Martirosyan
Scope: Extension application to introduce a new pharmaceutical form (orodispersible tablet)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Pretomanid - DOVPRELA (CAP) - EMEA/H/C/005167/II/0019/G, Orphan

Applicant: Mylan IRE Healthcare Limited
PRAC Rapporteur: Liana Martirosyan
Scope: Grouped application comprising two variations as follows:
Type II (C.I.4) – Update of sections 4.1 and 5.1 of the SmPC in order to rephrase the indication wording to align with the current WHO definitions. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet.
Type IB (C.I.11.z) - Submission of an updated RMP version 2.0 in order to align the safety concerns following the assessment of procedure EMEA/H/C/005167/11/0013

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.27. Rilpivirine - EDURANT (CAP) - EMEA/H/C/002264/X/0042/G

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Liana Martirosyan
Scope: Grouped application consisting of: 1) Extension application to introduce a new pharmaceutical form associated with new strength (2.5 mg dispersible tablets). The new presentation is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in patients ≥2 to <18 years of age and weighing at least 10 kg to less than 25 kg. The product information and RMP have been updated in accordance. 2) Type II variation (C.I.6.a) to modify the approved therapeutic indication of the already authorised 25 mg film-coated tablets presentation to include, in combination with other antiretroviral medicinal products, treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve and virologically suppressed (HIV-1 RNA less than 50 copies per ml) paediatric patients from 2 to less than 12 years weighing at least 25 kg, based on final results from study studies TMC278-TiDP38-C213 Cohort 2. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet and labelling are updated in accordance. The updated RMP version 10.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to Annex II and to update the list of local representatives in the package leaflet

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.28. Smallpox vaccine (live modified vaccinia virus Ankara) - IMVANEX (CAP) - EMEA/H/C/002596/II/0100

Applicant: Bavarian Nordic A/S
PRAC Rapporteur: Gabriele Maurer

Scope: Update of section 5.1 of the SmPC in order to add vaccine effectiveness data, and the removal of the two open specific obligations (POX-MVA-039 (SOB02) and SEMVAc (SOB03)), based on the IMVANEX vaccine effectiveness data in real-world use during the 2022 monkeypox outbreak. Consequently, the MAH proposes a switch from exceptional marketing authorisation to full marketing authorisation. The Annex II and package leaflet are updated accordingly. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.29. Teclistamab - TECVAYLI (CAP) - EMEA/H/C/005865/II/0012

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Jana Lukacisinova

Scope: Update of sections 4.2, 4.8, 5.1 of the SmPC in order to amend the recommendations for dose delays, as well as, to update safety and efficacy information based on final results from study 64007957MMY1001 listed as a specific obligation in the Annex II (SOB/005); this is a phase 1/2, first in human, open label, dose escalation study of teclistamab in subjects with relapsed or refractory multiple myeloma. The package leaflet is updated accordingly. The RMP version 4.2 has also been submitted. In addition, the MAH took the opportunity to update Annex II and Annex IV of the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.30. Tildrakizumab - ILUMETRI (CAP) - EMEA/H/C/004514/II/0054

Applicant: Almirall S.A

PRAC Rapporteur: Adam Przybylkowski

Scope: Update of section 5.1 of the SmPC in order to update clinical and safety information based on long-term results from the extension periods of the pivotal clinical studies MK-3222-010 (a 64-week, phase 3, randomised, placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (SCH 900222/MK-3222), followed by an optional long-term safety extension study, in subjects with moderate-to-severe chronic plaque psoriasis (Protocol No. MK-3222-010)) and MK-3222-011 (A 52-Week, Phase 3, Randomised, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222 / MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis). The RMP version 1.4 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.31. Tislelizumab - TEVIMBRA (CAP) - EMEA/H/C/005919/II/0006

Applicant: Beigene Ireland Limited

PRAC Rapporteur: Bianca Mulder
Scope: Extension of indication to include in combination with platinum and fluoropyrimidine-based chemotherapy the first-line treatment of adult patients with human epidermal growth factor receptor-2 (HER-2)-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma for TEVIMBRA, based on results from the phase 3 study BGB-A317-305 (study 305); this is a global, randomised, double-blind, placebo-controlled study at the approved registrational dosing regimen for Tevimbra (200 mg administered IV Q3W), in combination with platinum and fluoropyrimidine-based chemotherapy, in adult patients with HER-2 negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP.

### 5.3.32. Tislelizumab - TEVIMBRA (CAP) - EMEA/H/C/005919/II/0008

Applicant: Beigene Ireland Limited
PRAC Rapporteur: Bianca Mulder

Scope: Extension of indication to include treatment of adult patients with non-small cell lung cancer (NSCLC) in combination and as monotherapy for TEVIMBRA, based on results from studies BGB-A317-303, BGB-A317-304, BGB-A317-307 and BGB A317-206. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP.

### 5.3.33. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/II/0052

Applicant: AbbVie Deutschland GmbH & Co. KG
PRAC Rapporteur: Petar Mas

Scope: Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to change posology recommendations in adolescents with atopic dermatitis to include the 30mg dose option based on results from studies M16-045, M16-047 and M18-891 (pivotal phase 3 studies with adolescent substudies). The package leaflet is updated accordingly. The RMP version 14.0 has also been submitted.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP.
6. **Periodic safety update reports (PSURs)**

6.1. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only**

### 6.1.1. Abaloparatide - ELADYNOS (CAP) - PSUSA/00011029/202310
- **Applicant:** Theramex Ireland Limited
- **PRAC Rapporteur:** Karin Erneholm
- **Scope:** Evaluation of a PSUSA procedure
  - **Action:** For adoption of recommendation to CHMP

### 6.1.2. Acalabrutinib - CALQUENCE (CAP) - PSUSA/00010887/202310 (with RMP)
- **Applicant:** AstraZeneca AB
- **PRAC Rapporteur:** Barbara Kovacic Bytyqi
- **Scope:** Evaluation of a PSUSA procedure
  - **Action:** For adoption of recommendation to CHMP

### 6.1.3. Afatinib - GIOTRIF (CAP) - PSUSA/00010054/202309
- **Applicant:** Boehringer Ingelheim International GmbH
- **PRAC Rapporteur:** Ulla Wändel Liminga
- **Scope:** Evaluation of a PSUSA procedure
  - **Action:** For adoption of recommendation to CHMP

### 6.1.4. Andexanet alfa - ONDEXXYA (CAP) - PSUSA/00010764/202310
- **Applicant:** AstraZeneca AB
- **PRAC Rapporteur:** Bianca Mulder
- **Scope:** Evaluation of a PSUSA procedure
  - **Action:** For adoption of recommendation to CHMP

### 6.1.5. Arsenic trioxide - TRISENOX (CAP) - PSUSA/00000235/202309
- **Applicant:** Teva B.V.
- **PRAC Rapporteur:** Tiphaine Vaillant
- **Scope:** Evaluation of a PSUSA procedure
  - **Action:** For adoption of recommendation to CHMP
6.1.6. **Asciminib - SCEMBLIX (CAP) - PSUSA/00011008/202310**

Applicant: Novartis Europharm Limited  
PRAC Rapporteur: Eva Jirsová  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

6.1.7. **Axicabtagene ciloleucel - YESCARTA (CAP) - PSUSA/00010703/202310**

Applicant: Kite Pharma EU B.V.  
PRAC Rapporteur: Karin Erneholm  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

6.1.8. **Aztreonam4 - CAYSTON (CAP) - PSUSA/00000283/202309**

Applicant: Gilead Sciences Ireland UC  
PRAC Rapporteur: Liana Martirosyan  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

6.1.9. **Bexarotene - TARGRETIN (CAP) - PSUSA/00000404/202309**

Applicant: Eisai GmbH  
PRAC Rapporteur: Tiphaine Vaillant  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

6.1.10. **Brolucizumab - BEOVU (CAP) - PSUSA/00010829/202310**

Applicant: Novartis Europharm Limited  
PRAC Rapporteur: Gabriele Maurer  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

6.1.11. **Bupivacaine5 - EXPAREL LIPOSOMAL (CAP) - PSUSA/00010889/202310**

Applicant: Pacira Ireland Limited  
PRAC Rapporteur: Eamon O’Murchu

---

4 For inhalation use only  
5 Liposomal formulations only
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.12. Cetuximab - ERBITUX (CAP) - PSUSA/00000635/202309

Applicant: Merck Europe B.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.13. Chenodeoxycholic acid⁶ - CHENODEOXYCHOLIC ACID LEADIANT (CAP) - PSUSA/00010590/202310

Applicant: Leadiant GmbH
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP


Applicant: Pharming Group N.V
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.15. Coronavirus (COVID-19) vaccine (recombinant protein receptor binding domain fusion heterodimer) - BIMERVAX (CAP) - PSUSA/00011045/202309

Applicant: Hipra Human Health S.L.
PRAC Rapporteur: Zane Neikena
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.16. Dapagliflozin - EDISTRIDE (CAP); FORXIGA (CAP) - PSUSA/00010029/202310

Applicant: AstraZeneca AB
PRAC Rapporteur: Mari Thorn
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

⁶ Inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only
<table>
<thead>
<tr>
<th>6.1.17.</th>
<th>Delamanid - DELTYBA (CAP) - PSUSA/00010213/202310</th>
</tr>
</thead>
<tbody>
<tr>
<td>** Applicant:** Otsuka Novel Products GmbH</td>
<td></td>
</tr>
<tr>
<td>** PRAC Rapporteur:** Jo Robays</td>
<td></td>
</tr>
<tr>
<td>** Scope:** Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td>** Action:** For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6.1.18.</th>
<th>Denosumab(^7) - XGEVA (CAP) - PSUSA/00009119/202309</th>
</tr>
</thead>
<tbody>
<tr>
<td>** Applicant:** Amgen Europe B.V.</td>
<td></td>
</tr>
<tr>
<td>** PRAC Rapporteur:** Mari Thorn</td>
<td></td>
</tr>
<tr>
<td>** Scope:** Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td>** Action:** For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6.1.19.</th>
<th>Dexamethasone(^8) - NEOFORDEX (CAP) - PSUSA/00010480/202309</th>
</tr>
</thead>
<tbody>
<tr>
<td>** Applicant:** Theravia</td>
<td></td>
</tr>
<tr>
<td>** PRAC Rapporteur:** Tiphaine Vaillant</td>
<td></td>
</tr>
<tr>
<td>** Scope:** Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td>** Action:** For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6.1.20.</th>
<th>Dostarlimab - JEMPERLI (CAP) - PSUSA/00010931/202310</th>
</tr>
</thead>
<tbody>
<tr>
<td>** Applicant:** GlaxoSmithKline (Ireland) Limited</td>
<td></td>
</tr>
<tr>
<td>** PRAC Rapporteur:** Carla Torre</td>
<td></td>
</tr>
<tr>
<td>** Scope:** Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td>** Action:** For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6.1.21.</th>
<th>Eculizumab - BEKEMV (CAP); EPYSQLI (CAP); SOLIRIS (CAP) - PSUSA/00001198/202310</th>
</tr>
</thead>
<tbody>
<tr>
<td>** Applicant(s):** Alexion Europe SAS (Soliris), Amgen Technology (Ireland) Unlimited Company (Bekemv), Samsung Bioepis NL B.V. (Epysqli)</td>
<td></td>
</tr>
<tr>
<td>** PRAC Rapporteur:** Monica Martinez Redondo</td>
<td></td>
</tr>
<tr>
<td>** Scope:** Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td>** Action:** For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

---

\(^7\) Indicated for skeletal related events associated with bone metastases and for giant cell tumour of bone only

\(^8\) Centrally authorised product indicated in symptomatic multiple myeloma
6.1.22. Edoxaban - LIXIANA (CAP); ROTEAS (CAP) - PSUSA/00010387/202310

Applicant(s): Berlin Chemie AG (Roteas), Daiichi Sankyo Europe GmbH (Lixiana)
PRAC Rapporteur: Nathalie Gault
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.23. Etravirine - INTELENCE (CAP) - PSUSA/00001335/202309

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Nathalie Gault
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.24. Futibatinib - LYTGOBI (CAP) - PSUSA/00000068/202309

Applicant: Taiho Pharma Netherlands B.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.25. Herpes zoster vaccine (recombinant, adjuvanted) - SHINGRIX (CAP) - PSUSA/00010678/202310

Applicant: GlaxoSmithkline Biologicals SA
PRAC Rapporteur: Sonja Hrabcik
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP


Applicant: Laboratoires Delbert
PRAC Rapporteur: Eamon O’Murchu
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.27. Indacaterol, glycopyrronium bromide - ULTIBRO BREEZHALER (CAP); ULUNAR BREEZHALER (CAP); XOTERNA BREEZHALER (CAP) - PSUSA/00010105/202309

Applicant: Novartis Europharm Limited

⁹ Indicated for acute myeloid leukemia only
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.28. Insulin aspart - FIASP (CAP); INSULIN ASPART SANOFI (CAP); KIRSTY (CAP);
NOVOMIX (CAP); NOVORAPID (CAP); TRUVELOG MIX 30 (SRD) (CAP) -
PSUSA/00001749/202309

Applicant(s): Biosimilar Collaborations Ireland Limited (Kirsty), Novo Nordisk A/S (Fiasp,
NovoMix, NovoRapid), Sanofi Winthrop Industrie (Insulin aspart Sanofi, Truvelog Mix 30
(SRD))
PRAC Rapporteur: Mari Thorn
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.29. Insulin degludec – TRESIBA; insulin degludec, insulin aspart - RYZODEG (CAP);
(CAP) - PSUSA/00010036/202309

Applicant: Novo Nordisk A/S
PRAC Rapporteur: Mari Thorn
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.30. Insulin human\textsuperscript{10} - INSUMAN (CAP) - PSUSA/00010107/202309

Applicant: Sanofi-Aventis Deutschland GmbH
PRAC Rapporteur: Jean-Michel Dogné
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.31. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) - PSUSA/00010868/202310

Applicant: Vertex Pharmaceuticals (Ireland) Limited
PRAC Rapporteur: Martin Huber
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.32. Lasmiditan - RAYVOW (CAP) - PSUSA/00011011/202310

Applicant: Eli Lilly Nederland B.V.

\textsuperscript{10} For intraperitoneal use only
PRAC Rapporteur: Anna Mareková
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

**6.1.33. Loncastuximab tesirine - ZYNLONTA (CAP) - PSUSA/00011027/202310**

Applicant: Swedish Orphan Biovitrum AB (publ)
PRAC Rapporteur: Eva Jirsová
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

**6.1.34. Mavacamten - CAMZYOS (CAP) - PSUSA/00000074/202310**

Applicant: Bristol-Myers Squibb Pharma EEIG
PRAC Rapporteur: Kimmo Jaakkola
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

**6.1.35. Nintedanib\(^{11}\) - OFEV (CAP) - PSUSA/00010319/202310**

Applicant: Boehringer Ingelheim International GmbH
PRAC Rapporteur: Barbara Kovacic Bytyqi
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

**6.1.36. Niraparib, abiraterone acetate - AKEEGA (CAP) - PSUSA/00011051/202310**

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

**6.1.37. Nirsevimab - BEYFORTUS (CAP) - PSUSA/00011026/202310**

Applicant: Sanofi Winthrop Industrie
PRAC Rapporteur: Kimmo Jaakkola
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

\(^{11}\) Respiratory indication only
6.1.38. Parathyroid hormone - NATPAR (CAP) - PSUSA/00010591/202310

Applicant: Takeda Pharmaceuticals International AG Ireland Branch
PRAC Rapporteur: Rhea Fitzgerald
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.39. Pemigatinib - PEMAZYRE (CAP) - PSUSA/00010923/202310

Applicant: Incyte Biosciences Distribution B.V.
PRAC Rapporteur: Bianca Mulder
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.40. Pitolisant - OZAWADE (CAP); WAKIX (CAP) - PSUSA/00010490/202309

Applicant: Bioprojet Pharma
PRAC Rapporteur: Kirsti Villikka
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.41. Potassium citrate, potassium hydrogen carbonate - SIBNAYAL (CAP) - PSUSA/00010932/202310

Applicant: Advicenne
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.42. Regorafenib - STIVARGA (CAP) - PSUSA/00010133/202309

Applicant: Bayer AG
PRAC Rapporteur: Bianca Mulder
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.43. Recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E - AREXVY (CAP) - PSUSA/00000031/202311

Applicant: GlaxoSmithkline Biologicals S.A.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.44. Selumetinib - KOSELUGO (CAP) - PSUSA/00010936/202310

Applicant: AstraZeneca AB

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.45. Sirolimus\(^2\) - RAPAMUNE (CAP) - PSUSA/00002710/202309

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.46. Somatrogon - NGENLA (CAP) - PSUSA/00010982/202310

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.47. Sulfur hexafluoride - SONOVUE (CAP) - PSUSA/00002822/202309

Applicant: Bracco International B.V.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.48. Talazoparib - TALZENNA (CAP) - PSUSA/00010781/202310

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Carla Torre

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

\(^2\) For prophylaxis of organ rejection indication only
6.1.49.  **Talimogene laherparepvec - IMLYGIC (CAP) - PSUSA/00010459/202310**

Applicant: Amgen Europe B.V., ATMP  
PRAC Rapporteur: Gabriele Maurer  
Scope: Evaluation of a PSUSA procedure  
Action: For adoption of recommendation to CAT and CHMP

6.1.50.  **Toremifene - FARESTON (CAP) - PSUSA/00002999/202309**

Applicant: Orion Corporation  
PRAC Rapporteur: Tiphaine Vaillant  
Scope: Evaluation of a PSUSA procedure  
Action: For adoption of recommendation to CHMP

6.1.51.  **Tremelimumab - IMJUDO (CAP) - PSUSA/00011038/202310**

Applicant: AstraZeneca AB  
PRAC Rapporteur: David Olsen  
Scope: Evaluation of a PSUSA procedure  
Action: For adoption of recommendation to CHMP

6.1.52.  **Tucatinib - TUKYSA (CAP) - PSUSA/00010918/202310**

Applicant: Seagen B.V.  
PRAC Rapporteur: Jean-Michel Dogné  
Scope: Evaluation of a PSUSA procedure  
Action: For adoption of recommendation to CHMP

6.1.53.  **Volanesorsen - WAYLIVRA (CAP) - PSUSA/00010762/202311**

Applicant: Akcea Therapeutics Ireland Limited  
PRAC Rapporteur: Martin Huber  
Scope: Evaluation of a PSUSA procedure  
Action: For adoption of recommendation to CHMP

6.1.54.  **Zoonotic influenza vaccine (H5N1)\(^{13}\) - FOCLIVIA (CAP); prepandemic influenza vaccine (H5N1)\(^{13}\) - AFLUNOV (CAP); ZOONOTIC INFLUENZA VACCINE SEQIRUS (CAP) - PSUSA/00010008/202310**

Applicant: Seqirus S.r.l.

\(^{13}\) Surface antigen, inactivated, adjuvanted
**6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)**

**6.2.1. Buprenorphine\(^{14}\) - BUVIDAL (CAP); NAP - PSUSA/00000459/202309**

Applicant: Camurus AB (Buvidal), various

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

**6.2.2. Buprenorphine, naloxone - SUBOXONE (CAP); ZUBSOLV (CAP); NAP - PSUSA/00002113/202309**

Applicant(s): Accord Healthcare S.L.U. (Zubsolv), Indivior Europe Limited (Suboxone), various

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

**6.2.3. Iloprost\(^{15}\) - VENTAVIS (CAP); NAP - PSUSA/00001724/202309**

Applicant: Bayer AG (Ventavis), various

PRAC Rapporteur: Nathalie Gault

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

**6.2.4. Leflunomide - ARAVA (CAP); LEFLUNOMIDE MEDAC (CAP); LEFLUNOMIDE ZENTIVA (CAP); NAP - PSUSA/00001837/202309**

Applicant(s): Medac Gesellschaft fur klinische Spezialpraparate mbH (Leflunomide medac), Sanofi-Aventis Deutschland GmbH (Arava), Zentiva, k.s. (Leflunomide Zentiva), various

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

\(^{14}\) All formulations except implants

\(^{15}\) Nebuliser solution only
### 6.2.5. Melatonin - CIRCADIN (CAP); MELATONIN NEURIM (CAP); SLENYTO (CAP); NAP - PSUSA/00001963/202309

**Applicant:** RAD Neurim Pharmaceuticals EEC SARL (Circadin, Melatonin Neurim, Slenyto), various  
**PRAC Rapporteur:** Ana Sofia Diniz Martins  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.2.6. Memantine - AXURA (CAP); EBIXA (CAP); MEMANTINE MERZ (CAP); NAP - PSUSA/00001967/202309

**Applicant(s):** H. Lundbeck A/S (Ebixa), Merz Pharmaceuticals GmbH (Axura, Memantine Merz), various  
**PRAC Rapporteur:** Maria del Pilar Rayon  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.2.7. Posaconazole - NOXAFIL (CAP); NAP - PSUSA/00002480/202310

**Applicant:** Merck Sharp & Dohme B.V. (Noxafil), various  
**PRAC Rapporteur:** Nathalie Gault  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.2.8. Sodium oxybate\(^\text{16}\) - XYREM (CAP); NAP - PSUSA/00010612/202310

**Applicant:** UCB Pharma S.A. (Xyrem), various  
**PRAC Rapporteur:** Ana Sofia Diniz Martins  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.2.9. Teriflunomide - AUBAGIO (CAP); TERYFLUNOMIDE ACCORD (CAP); TERYFLUNOMIDE MYLAN (CAP); NAP - PSUSA/00010135/202309

**Applicant(s):** Accord Healthcare S.L.U. (Teriflunomide Accord), Mylan Pharmaceuticals Limited (Teriflunomide Mylan), Sanofi Winthrop Industrie (AUBAGIO), various  
**PRAC Rapporteur:** Martin Huber  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

---

\(^{16}\) Oral use
6.2.10. **Vigabatrin - KIGABEQ (CAP); NAP - PSUSA/00003112/202309**

Applicant: ORPHELIA Pharma SAS (Kigabeq), various
PRAC Rapporteur: Kirsti Villikka
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only**

6.3.1. **Acetylcysteine (NAP) - PSUSA/00000034/202309**

Applicant(s): various
PRAC Lead: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.2. **Acitretin (NAP) - PSUSA/00000051/202310**

Applicant(s): various
PRAC Lead: Marie Louise Schougaard Christiansen
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.3. **Adapalene, benzoyl peroxide (NAP) - PSUSA/00000059/202309**

Applicant(s): various
PRAC Lead: Mari Thorn
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.4. **Baclofen\(^\text{17}\) (NAP) - PSUSA/00000294/202309**

Applicant(s): various
PRAC Lead: Eamon O'Murchu
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

\(^{17}\) Oral use, for muscle spasticity indication only
6.3.5. Calcium carbonate, famotidine, magnesium hydroxide (NAP) - PSUSA/00001351/202309

Applicant(s): various
PRAC Lead: Nathalie Gault
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.6. Desflurane (NAP) - PSUSA/00000958/202309

Applicant(s): various
PRAC Lead: Melinda Palfi
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.7. Diclofenac\(^\text{18}\) (NAP) - PSUSA/00010342/202309

Applicant(s): various
PRAC Lead: Karin Erneholm
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.8. Felodipine, ramipril (NAP) - PSUSA/00001358/202309

Applicant(s): various
PRAC Lead: Martin Huber
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.9. Human von Willebrand factor (NAP) - PSUSA/00001642/202309

Applicant(s): various
PRAC Lead: Gabriele Maurer
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.10. Levofloxacin\(^\text{19}\) (NAP) - PSUSA/00010767/202310

Applicant(s): various

---

\(^{18}\) Topical formulations only
\(^{19}\) Intravenous and oral use only
### 6.3.11. Levofloxacin\(^20\) (NAP) - PSUSA/00010768/202310

Applicant(s): various  
PRAC Lead: Martin Huber  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

### 6.3.12. Prulifloxacin (NAP) - PSUSA/00002569/202309

Applicant(s): various  
PRAC Lead: Amelia Cupelli  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

### 6.3.13. Rubidium (\(^{82}\)Rb) chloride (NAP) - PSUSA/00010806/202310

Applicant(s): various  
PRAC Lead: Martin Huber  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

### 6.4. Follow-up to PSUR/PSUSA procedures

#### 6.4.1. Tenofovir disoproxil - VIREAD (CAP) - EMEA/H/C/000419/LEG 279

Applicant: Gilead Sciences Ireland UC  
PRAC Rapporteur: Nathalie Gault  
Scope: From PSUSA/00002892/202303: Cumulative safety review on dental disorders, increased parathyroid hormone and congenital anomalies  
**Action:** For adoption of advice to CHMP

---

\(^{20}\) Ocular use only
6.5. Variation procedure(s) resulting from PSUSA evaluation

6.5.1. Dabrafenib - FINLEE (CAP) - EMEA/H/C/005885/WS2671/0005; Trametinib - SPEXOTRAS (CAP) - EMEA/H/C/005886/WS2671/0004; Dabrafenib - TAFINLAR (CAP) - EMEA/H/C/002604/WS2671/0067

Applicant: Novartis Europharm Limited
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Update of section 4.8 of the SmPC for Tafinlar, Finlee and Spexotras in order to add ‘Atrioventricular (AV) block’ and ‘Bundle branch block’ to the list of adverse drug reactions (ADRs), following the PRAC recommendation in the PSUR for Mekinist (PSUSA/00010262/202305). The package leaflet is updated accordingly
Action: For adoption of PRAC Assessment Report

6.5.2. Ioflupane (123I) - DATSCAN (CAP) - EMEA/H/C/000266/II/0067

Applicant: GE Healthcare B.V.
PRAC Rapporteur: Tiphaine Vaillant
Scope: To update sections 4.4 and 4.5 of the SmPC and section 2 of the Package Leaflet to implement the recommendation of PRAC following the PSUSA procedure (EMEA/H/C/PSUSA/00001767/202207). In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet.
Action: For adoption of PRAC Assessment Report

6.5.3. Mitotane - LYSODREN (CAP) - EMEA/H/C/000521/II/0030

Applicant: HRA Pharma Rare Diseases
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Update of section 4.4 of the SmPC in order amend an existing warning on hepatic impairment based on a cumulative review of cases with increase of transaminases >5 ULN and the outcome of these elevations after mitotane discontinuation, following the request by PRAC in the PSUSA/00002075/202304
Action: For adoption of PRAC Assessment Report

6.5.4. Naltrexone hydrochloride, Bupropion hydrochloride - MYSIMBA (CAP) - EMEA/H/C/003687/II/0063

Applicant: Orexigen Therapeutics Ireland Limited
PRAC Rapporteur: Martin Huber
Scope: Submission of an update of sections 4.3, 4.4 and 4.5 of the SmPC to update and streamline the relevant wording on opioids as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00010366/202209) adopted in April 2023.
The package leaflet is updated accordingly. The RMP version 12.9 has also been submitted.

**Action:** For adoption of PRAC Assessment Report

### 6.5.5. Rituximab - MABTHERA (CAP) - EMEA/H/C/000165/II/0201/G

**Applicant:** Roche Registration GmbH  
**PRAC Rapporteur:** Karin Erneholm  
**Scope:** A grouped application comprising of:

Type II (C.I.3.b): Update of sections 4.1, 4.2, 4.3, 4.8, 5.1, 6.2, 6.4 and 6.5 of the SmPC in order to introduce several structural and editorial changes to align with the current SmPC guideline and to remove the educational materials for healthcare professionals (HCPs) and patients, following the request by PRAC in the assessment report for the PSUSA procedure EMA/PRAC/257005/2023. The Annex II, Labelling and package leaflet are updated accordingly. The RMP version 25.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information and to update the list of local representatives in the package leaflet. Type I (A.6): To change the ATC Code of rituximab from L01XC02 to L01FA01

**Action:** For adoption of PRAC Assessment Report

### 6.6. Expedited summary safety reviews\(^{21}\)

None

### 7. Post-authorisation safety studies (PASS)

#### 7.1. Protocols of PASS imposed in the marketing authorisation(s)\(^{22}\)

#### 7.1.1. Axicabtagene ciloleucel (CAP) - YESCARTA – EMEA/H/C/PSA/S/0102.4

**Applicant:** Kite Pharma EU B.V.  
**PRAC Rapporteur:** Karin Erneholm  
**Scope:** Substantial amendment to a protocol for a long-term, non-interventional study of recipients of Yescarta for treatment of relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma [MAH’s response to PSA/S/0102.3]

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

---

21 Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC  
22 In accordance with Article 107n of Directive 2001/83/EC
7.1.2. **Evinacumab - EVKEEZA (CAP) – EMEA/H/C/PSA/S/0112**

Applicant: Regeneron Ireland DAC  
PRAC Rapporteur: Mari Thorn  
Scope: Substantial amendment to a protocol for an evaluation of the long-term effects of evinacumab treatment in patients with homozygous familial hypercholesterolemia (HoFH):  
• safety outcomes in patients with HoFH who are $\geq$ 12 years old  
• frequency and outcomes of pregnancy in female patients with HoFH  
• atherosclerosis process over time in patients with HoFH who undergo cardiovascular imaging (as data allow)  
• frequency of cardiovascular imaging of patients with HoFH  

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.3. **Methylphenidate hydrochloride (NAP) – EMEA/H/N/PSA/S/0113**

Applicant: Medice Arzneimittel Pütter GmbH Co. KG (MAH for Medikinet)  
PRAC Rapporteur: Martin Huber  
Scope: Substantial amendments to the protocol for the post-authorisation safety study (PASS) evaluating the long-term cardiovascular and psychiatric safety profile of methylphenidate in adult patients with attention deficit/hyperactivity disorder (ADHD) in European Countries. A revised protocol version 5.2 dated 2 February 2024 was submitted. The most significant changes introduced by the amended protocol concern the study milestones and the data analysis  

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.4. **Pegzilarginase - LOARGYS (CAP) – EMEA/H/C/PSP/S/0105**

Applicant: Immedica Pharma AB  
PRAC Rapporteur: Martin Huber  
Scope: A European, non-interventional, multicentre, registry-based PASS to evaluate the long-term safety of Loargys treatment in arginase 1 deficiency patients in standard clinical care  

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.5. **Valproate (CAP) – EMEA/H/N/PSP/J/0074.9**

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)  
PRAC Rapporteur: Jean-Michel Dogné  
Scope: Responses to the 2nd request for supplementary information (RSI) of the 2nd interim report: observational study to evaluate and identify the best practices for switching of valproate in clinical practice [MAH's response to PSP/J/0074.8], non-interventional retrospective longitudinal study in the UK and France to investigate the therapeutic strategies after discontinuation of valproate (VPA) and related substances in clinical
practice: VALSE study (VALNAC09344)

- Response document to PRAC assessment report (Procedure no.: EMEA/H/N/PSP/J/0074.7)
- Sensitivity analysis performed in the SNDS database, the national healthcare data system in France, to specify the indication for the use of valproate and reduce the proportion of women with unspecified indication.

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.2. Protocols of PASS non-imposed in the marketing authorisation(s)\(^{23}\)

#### 7.2.1. Abaloparatide - ELADYNOS (CAP) - EMEA/H/C/005928/MEA 001.2

**Applicant:** Theramex Ireland Limited  
**PRAC Rapporteur:** Karin Erneholm  
**Scope:** From initial marketing authorisation application (MAA): REVISED PASS PROTOCOL (Study number not assigned yet); Non-imposed/non-interventional; European non-interventional post-authorisation safety study (PASS) to assess serious cardiovascular events of myocardial infarction (MI), stroke, all-cause and cardiovascular mortality, and arrhythmias for abaloparatide  
**Action:** For adoption of advice to CHMP

#### 7.2.2. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/MEA 007.17

**Applicant:** Sanofi Belgium  
**PRAC Rapporteur:** Karin Erneholm  
**Scope:** MAH's response to MEA 007.14 [Amended Protocol OBS13434 version 4]; request for supplementary information (RSI) as adopted in October 2023. A prospective, multicentre, observational, post-authorisation safety study to evaluate the long-term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis  
**Action:** For adoption of advice to CHMP

#### 7.2.3. Atogepant - AQUIPTA (CAP) - EMEA/H/C/005871/MEA 003

**Applicant:** AbbVie Deutschland GmbH & Co. KG  
**PRAC Rapporteur:** Rugile Pilviniene  
**Scope:** Study P22-392; Atogepant pregnancy exposure registry: Study P22-392 aims to prospectively evaluate maternal, foetal, and infant outcomes through 12 months of age among women exposed to atogepant during pregnancy  
**Action:** For adoption of advice to CHMP

---

\(^{23}\) In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004
7.2.4. **Atogepant - AQUIPTA (CAP) - EMEA/H/C/005871/MEA 004**

Applicant: AbbVie Deutschland GmbH & Co. KG  
PRAC Rapporteur: Rugile Pilviniene  
Scope: Study P22-419; Pregnancy Study; Study P22-419 aims to describe and compare the incidence of pregnancy outcomes in women with migraine who are exposed to atogepant during pregnancy  
**Action:** For adoption of advice to CHMP

7.2.5. **Dabigatran etexilate - PRADAXA (CAP) - EMEA/H/C/000829/MEA 051.2**

Applicant: Boehringer Ingelheim International GmbH  
PRAC Rapporteur: Marie Louise Schougaard Christiansen  
Scope: From X/0122/G: REVISED PROTOCOL (3.0) for PASS 1160.307 (non-imposed); Safety of dabigatran etexilate for treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 2 years of age: A European non-interventional cohort study based on new data collection  
**Action:** For adoption of advice to CHMP

7.2.6. **Glofitamab - COLUMVI (CAP) - EMEA/H/C/005751/MEA 004**

Applicant: Roche Registration GmbH  
PRAC Rapporteur: Jana Lukacisinova  
Scope: From initial MAA; PASS No BO43309 (non-imposed/non-interventional); Evaluation of the Effectiveness of the Additional Risk Minimisation Measures for Glofitamab - A Survey Among Healthcare Professionals in 10 Countries in the European Economic Area (EEA)  
**Action:** For adoption of advice to CHMP

7.2.7. **Neratinib - NERLYNX (CAP) - EMEA/H/C/004030/MEA 003.3**

Applicant: Pierre Fabre Medicament  
PRAC Rapporteur: Bianca Mulder  
Scope: Amended Protocol / Study PUMA-NER-7402 (version 4.0); Safety of neratinib among breast cancer patients to characterise the incidence and duration of diarrhoea in a real-world setting, describe patient characteristics, incidence rates and duration of diarrhoea, describe use of loperamide and other concomitant antidiarrheal medication, describe adherence to neratinib therapy, assess the impact of neratinib therapy on patient self-reported, health related quality of life and their ability to perform their activities of daily living and to further assess and characterise adverse events hepatic, cardiac (LVEF decreased), pulmonary (interstitial lung disease), reproductive and developmental toxicity  
**Action:** For adoption of advice to CHMP
7.2.8.  **Niraparib, Abiraterone acetate - AKEEGA (CAP) - EMEA/H/C/005932/MEA 001.2**

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Jan Neuhauser
Scope: Revised PASS Protocol / Study no.: PCSONCA0485; Study title: Post authorisation safety study to characterise the risk of second primary malignancies (SPM) including MDS/AML among metastatic prostate cancer patients exposed to AKEEGA

**Action:** For adoption of advice to CHMP

7.2.9.  **Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/MEA 010.3**

Applicant: AbbVie Deutschland GmbH & Co. KG
PRAC Rapporteur: Liana Martirosyan
Scope: Revised PASS Protocol (v 2.1) / Study no.: P23-654 (Non-imposed/Non-interventional); Title: Long-Term Comparative Cohort Study in Patients with Crohn's Disease in a Real World Setting. Additional long-term data from the real-world experience of patients with Crohn's disease treated with risankizumab to assess product potential risks. A comparative cohort study will be conducted to estimate rates of malignancy (malignancy excluding NMSC, NMSC), serious infections, serious hypersensitivity reactions, and major adverse cardiovascular events (MACE) in risankizumab treated patients with Crohn's disease, relative to alternative systemic therapies (e.g., biologics). MAH's responses to MEA010.2 as adopted in January 2024: The current protocol insufficiently addresses whether duration of treatment (exposure) will be taken into account in the analysis of MACE and also for the other outcomes of interest. The MAH is requested to clarify whether duration of treatment (exposure) will be considered in the analysis of the outcomes of interest or otherwise include this consideration in the protocol

**Action:** For adoption of advice to CHMP

7.2.10.  **Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.10**

Applicant: UCB Pharma S.A.
PRAC Rapporteur: Tiphaine Vaillant
Scope: MAH's response to MEA 002.9 [Protocol Amendment for study OP0004] request for supplementary information as adopted in January 2024

**Action:** For adoption of advice to CHMP

7.2.11.  **Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.8**

Applicant: UCB Pharma S.A.
PRAC Rapporteur: Tiphaine Vaillant
Scope: MAH's response to MEA 003.7 [Protocol Amendment for study OP0006] request for supplementary information as adopted in January 2024

**Action:** For adoption of advice to CHMP
7.2.12. Ruxolitinib - OPZELURA (CAP) - EMEA/H/C/005843/MEA 001.1

Applicant: Incyte Biosciences Distribution B.V.
PRAC Rapporteur: Adam Przybylkowski
Scope: From Initial MAA: Revised protocol for PASS INCB 88888-037 (non-imposed non-interventional, RMP, Cat. 3); Title: To evaluate the safety of long-term ruxolitinib cream use with respect to incidence of non-melanoma skin cancers
Action: For adoption of advice to CHMP

7.2.13. Somapacitan - SOGROYA (CAP) - EMEA/H/C/005030/MEA 005.1

Applicant: Novo Nordisk A/S
PRAC Rapporteur: Martin Huber
Scope: From X/0006/G: Revised protocol / Study No. NN8640-4787; Paediatric growth hormone deficiency (GHD) register-based study: A non-interventional, observational, register-based study to investigate long-term safety and clinical parameters of somapacitan treatment in paediatric patients with GHD in the setting of routine clinical practice. As a follow-up of MEA 005.1, a revised protocol for the non-imposed, non-interventional PASS should be submitted in clean and change-track format taking into account the comments adopted by PRAC
Action: For adoption of advice to CHMP

7.2.14. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 025.3

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Liana Martirosyan
Scope: From initial MAA: PASS DUS A3921403 (non-imposed RMP Cat. 3); PASS of the utilisation and prescribing patterns of Xeljanz (tofacitinib) using an administrative healthcare database in France, is a descriptive drug utilisation study using real-world data collected from routine clinical care in France. The overall goal is to determine if there is evidence that prescribers in France are compliant with the recommendations and limitations for use described in the tofacitinib additional risk minimisation measures (aRMM) materials
Action: For adoption of advice to CHMP

7.3. Results of PASS imposed in the marketing authorisation(s)\textsuperscript{24}

7.3.1. Levofloxacin – QUINSAIR (CAP) - EMEA/H/C/PSR/S/0046

Applicant: Chiesi Farmaceutici S.p.A.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Final study report for a post-marketing, observational safety study of Quinsair (levofloxacin hemihydrate) in patients with cystic fibrosis to evaluate the long-term safety

\textsuperscript{24} In accordance with Article 107p-q of Directive 2001/83/EC
compared to other inhaled approved antibiotic therapies in cystic fibrosis patients

**Action:** For adoption of recommendation to CHMP (or request for supplementary information (RSI))

### 7.4. Results of PASS non-imposed in the marketing authorisation(s)\(^{25}\)

#### 7.4.1. Dolutegravir, Lamivudine - DOVATO (CAP) - EMEA/H/C/004909/WS2620/0047; Dolutegravir, Rilpivirine - JULUCA (CAP) - EMEA/H/C/004427/WS2620/0056; Dolutegravir - TIVICAY (CAP) - EMEA/H/C/002753/WS2620/0092; Dolutegravir, Abacavir, Lamivudine - TRIUMEQ (CAP) - EMEA/H/C/002754/WS2620/0118

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of section 4.6 of the SmPC in order to update information about the use of dolutegravir-containing regimens in pregnancy and at conception based on final results from non-interventional Tsepamo study and the Eswatini Birth Outcomes Surveillance study. In addition, data from other cohort studies and pregnancy registries, including the APR, DOLOMITE-EPPICC (Study 208613) and DOLOMITE-NEAT-ID Network study (Study 208759) both listed as category 3 studies in the RMP; and the US Chart Review (Study 212976) as well as data from literature are included. DOLOMITE-EPPICC (Study 208613) is a non-interventional study to Assess ‘real-world’ maternal and foetal outcomes following DTG use during pregnancy and to describe patterns of dolutegravir utilisation; DOLOMITE NEAT ID Network Study (208759) is a non-interventional, multi-site observational study to define the safety and effectiveness of dolutegravir use in HIV positive pregnant women. The package leaflet is updated accordingly. The RMP version 19 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to sections 4.4 and 4.5 of the SmPC

**Action:** For adoption of PRAC Assessment Report

#### 7.4.2. Epoetin alfa - ABSEAMED (CAP) - EMEA/H/C/000727/WS2615/0108; Epoetin alfa - BINOCRIT (CAP) - EMEA/H/C/000725/WS2615/0108; Epoetin alfa - EPOETIN ALFA HEXAL (CAP) - EMEA/H/C/000726/WS2615/0108

Applicant: Sandoz GmbH

PRAC Rapporteur: Tiphaine Vaillant

Scope: Submission of the final report from Non-Interventional Post authorisation Safety Study, NI-PASS HX575-507 listed as a category 3 study in the RMP. The non-interventional study (NIS PASS) study HX575-507 was conducted to address a post-approval requirement (MEA 13.5) to evaluate the safety profile of HX575 administered subcutaneous (s.c.) in patients with CKD-induced anaemia under real-life conditions, in order to increase confidence on the safe use of s.c. HX575. The RMP version 19.0 has also been submitted

**Action:** For adoption of PRAC Assessment Report

---

\(^{25}\) In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013
7.4.3. Guanfacine - INTUNIV (CAP) - EMEA/H/C/003759/II/0033/G

Applicant: Takeda Pharmaceuticals International AG Ireland Branch
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Submission of the final reports from the Drug Utilisation Study of Intuniv (guanfacine extended release) in European countries: a prescriber survey (EUPAS18739) and a retrospective database study (EUPAS18735), listed as category 3 studies in the RMP. The RMP version 4.0 has also been submitted
Action: For adoption of PRAC Assessment Report

7.4.4. Human normal immunoglobulin - HYQVIA (CAP) - EMEA/H/C/002491/II/0096

Applicant: Baxalta Innovations GmbH
PRAC Rapporteur: Gabriele Maurer
Scope: Update of sections 4.8 and 5.1 of the SmPC in order to update long-term safety information based on final results from studies 161406 ‘non-interventional post-marketing safety study on the long-term safety of HYQVIA (Global)’ listed as category 3 a study in the RMP and 161302 ‘non-interventional post-authorisation safety study on the long-term safety of HyQvia in subjects treated with HyQvia’. Both studies were non-interventional, prospective, uncontrolled, multicentre, open-label, post-authorisation studies. The RMP version 15.0 has also been submitted. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template version 10.3, to update the list of local representatives in the package leaflet and to introduce minor editorial changes to the product information
Action: For adoption of PRAC Assessment Report

7.4.5. Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0043

Applicant: Gruenenthal GmbH
PRAC Rapporteur: Eamon O’Murchu
Scope: Submission of the final report from the PASS study D3820R0008 listed as a category 3 study in the RMP. This is a US post-marketing, comparative, observational study to evaluate the cardiovascular safety of Naloxegol in patients with non-cancer pain in comparison to other treatments for opioid induced constipation. The RMP version 9.0 has also been submitted
Action: For adoption of PRAC Assessment Report

7.4.6. Piperaquine tetraphosphate, artenimol - EURARTESIM (CAP) - EMEA/H/C/001199/II/0040/G

Applicant: Alfasigma S.p.A.
PRAC Rapporteur: Martin Huber
Scope: Grouped variation consisting of: 1) Submission of the final report from the effectiveness evaluation survey for Eurartesim (protocol no. 3366) (listed as a category 3
study in the RMP): an European multi-centre online survey to assess physician understanding of the revised edition of the educational material. Consequential changes to RMP version 16.1 have been implemented; 2) Submission of an updated RMP version 16.1 in order to delete ‘severe malaria’ as missing information from the list of safety specifications

**Action:** For adoption of PRAC Assessment Report

### 7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

#### 7.5.1. Abatacept - ORENCIA (CAP) - EMEA/H/C/000701/MEA 048.12

**Applicant:** Bristol-Myers Squibb Pharma EEIG  
**PRAC Rapporteur:** Kimmo Jaakkola  
**Scope:** From II-0024: Study number: IM101240 JIA registry; Yearly Recruitment update in the context of MEA-048; An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis is ongoing. The primary objective is to describe the long-term safety of abatacept treatment for juvenile idiopathic arthritis (JIA) in routine clinical practice by quantifying the incidence rates of serious infections, autoimmune disorders, and malignancies. The data in these studies do not change the safety profile of abatacept. The MAH will supply interim reports from the above-mentioned studies according to the set schedules. Recruitment updates are provided each February, and interim reports will be submitted in 2014, 2019, and 2024. The planned date for submission of final data is 2029  
**Action:** For adoption of advice to CHMP

#### 7.5.2. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/ANX 009.6

**Applicant:** Sanofi Belgium  
**PRAC Rapporteur:** Karin Erneholm  
**Scope:** MAH’s response to MEA 009.4 request for supplementary information (RSI) and updated protocol [feasibility analysis report for the Cat. 1 non-interventional PASS to investigate the risk of mortality in multiple sclerosis (MS) patients treated with alemtuzumab (LEMTRADA) relative to comparable MS patients using other disease modifying treatments (DMTs)] as adopted by PRAC in January 2024  
**Action:** For adoption of advice to CHMP

#### 7.5.3. Chenodeoxycholic acid - CHENODEOXYCHOLIC ACID LEADIANT (CAP) - EMEA/H/C/004061/SOB 003.2

**Applicant:** Leadiant GmbH  
**PRAC Rapporteur:** Adam Przybylkowski  
**Scope:** Cerebrotendinous Xanthomatosis Registry: Long term Non-Interventional Follow-up of Safety and Effectiveness of Chenodeoxycholic Acid Leadiant. (Refer also to SOB-001) In order to collect long term safety and efficacy data in patients treated with
chenodeoxycholic acid, the MAH will submit the results of a study deriving from a registry of patients with inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency in infants, children and adolescents aged 1 month to 18 years and adults

**Action:** For adoption of advice to CHMP

### 7.5.4. Cinacalcet - MIMPARA (CAP) - EMEA/H/C/000570/MEA 035.9

**Applicant:** Amgen Europe B.V.

**PRAC Rapporteur:** Mari Thorn

**Scope:** From X-0055: Observational registry study (Study 20180204): To evaluate the risk of hypocalcaemia (e.g., clinical characteristics, laboratory variables [PTH, Ca, and P], hospitalisation due to hypocalcaemia, co-medication, cinacalcet doses) in paediatric patients treated with cinacalcet

**Action:** For adoption of advice to CHMP

### 7.5.5. Damoctocog alfa pegol - JIVI (CAP) - EMEA/H/C/004054/ANX 001.3

**Applicant:** Bayer AG

**PRAC Rapporteur:** Bianca Mulder

**Scope:** MAH's response to questions on ANX 001.2 [Second Interim Report: Study number 20904 (HA-SAFE)] as adopted in January 2024

**Action:** For adoption of advice to CHMP

### 7.5.6. Erenumab - AIMOVIG (CAP) - EMEA/H/C/004447/MEA 001.3

**Applicant:** Novartis Europharm Limited

**PRAC Rapporteur:** Kirsti Villikka

**Scope:** From Initial MAA: NIS - A Non-Interventional Study to examine patient characteristics and drug utilisation patterns in migraine patients treated with prophylactic drugs in the Nordic registries

**Action:** For adoption of advice to CHMP

### 7.5.7. Lenvatinib - LENVIMA (CAP) - EMEA/H/C/003727/MEA 014.7

**Applicant:** Eisai GmbH

**PRAC Rapporteur:** Ulla Wändel Liminga

**Scope:** From II-0011-G: Third annual progress report for PASS No. E7080-M000-508; HCC: To assess the severity of hepatotoxicity and factors that contribute to hepatotoxicity of lenvatinib, and the influence on overall survival in the Western population. A multicentre, observational post authorisation safety study (PASS), phase 4 study to evaluate the safety and tolerability of lenvatinib in patients with advanced or unresectable hepatocellular carcinoma (STELLAR)

**Action:** For adoption of advice to CHMP
7.5.8. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 054.2

Applicant: BioNTech Manufacturing GmbH
PRAC Rapporteur: Liana Martirosyan
Scope: Study C4591022; Pfizer-BioNTech COVID-19 Vaccine Exposure during Pregnancy: A Non-Interventional Post-Approval Safety Study of Pregnancy and Infant Outcomes in the Organization of Teratology Information Specialists (OTIS)/MotherToBaby Pregnancy Registry

Action: For adoption of advice to CHMP

7.6. Others

None

7.7. New Scientific Advice

None

7.8. Ongoing Scientific Advice

None

7.9. Final Scientific Advice (Reports and Scientific Advice letters)

None

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation

8.1.1. Glucarpidase - VORAXAZE (CAP) - EMEA/H/C/005467/S/0025 (without RMP)

Applicant: SERB S.A.S.
PRAC Rapporteur: Martin Huber
Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.2. Histamine dihydrochloride - CEPLENE (CAP) - EMEA/H/C/000796/S/0048 (without RMP)

Applicant: Laboratoires Delbert
PRAC Rapporteur: Eamon O’Murchu
Scope: Annual reassessment of the marketing authorisation
**Action:** For adoption of advice to CHMP

### 8.1.3. Susoctocog alfa - OBIZUR (CAP) - EMEA/H/C/002792/S/0056 (without RMP)

- **Applicant:** Baxalta Innovations GmbH
- **PRAC Rapporteur:** Gabriele Maurer
- **Scope:** Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.1.4. Tabelecleucel - EBVALLO (CAP) - EMEA/H/C/004577/S/0008 (without RMP)

- **Applicant:** Pierre Fabre Medicament, ATMP
- **PRAC Rapporteur:** Amelia Cupelli
- **Scope:** Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CAT and CHMP

### 8.1.5. Tagraxofusp - ELZONRIS (CAP) - EMEA/H/C/005031/S/0025 (without RMP)

- **Applicant:** Stemline Therapeutics B.V.
- **PRAC Rapporteur:** Bianca Mulder
- **Scope:** Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.1.6. Tecovirimat - TECOVIRIMAT SIGA (CAP) - EMEA/H/C/005248/S/0010 (without RMP)

- **Applicant:** SIGA Technologies Netherlands B.V.
- **PRAC Rapporteur:** Martin Huber
- **Scope:** Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.2. Conditional renewals of the marketing authorisation

### 8.2.1. Avapritinib - AYVAKYT (CAP) - EMEA/H/C/005208/R/0034 (without RMP)

- **Applicant:** Blueprint Medicines (Netherlands) B.V.
- **PRAC Rapporteur:** Bianca Mulder
- **Scope:** Conditional renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP
### 8.2.2. Epcoritamab - TEPKINLY (CAP) - EMEA/H/C/005985/R/0004 (without RMP)

- **Applicant:** AbbVie Deutschland GmbH & Co. KG
- **PRAC Rapporteur:** Monica Martinez Redondo
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.2.3. Imlifidase - IDEFIRIX (CAP) - EMEA/H/C/004849/R/0020 (without RMP)

- **Applicant:** Hansa Biopharma AB
- **PRAC Rapporteur:** Bianca Mulder
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.2.4. Larotrectinib - VITRAKVI (CAP) - EMEA/H/C/004919/R/0035 (without RMP)

- **Applicant:** Bayer AG
- **PRAC Rapporteur:** Rugile Pilviniene
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.2.5. Tafasitamab - MINJUVI (CAP) - EMEA/H/C/005436/R/0015 (without RMP)

- **Applicant:** Incyte Biosciences Distribution B.V.
- **PRAC Rapporteur:** Ulla Wändel Liminga
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.2.6. Valoctocogene roxaparvovec - ROCTAVIAN (CAP) - EMEA/H/C/005830/R/0011 (with RMP)

- **Applicant:** BioMarin International Limited, ATMP
- **PRAC Rapporteur:** Bianca Mulder
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CAT and CHMP
8.3. Renewals of the marketing authorisation

8.3.1. Arsenic trioxide - ARSENIC TRIOXIDE ACCORD (CAP) - EMEA/H/C/005175/R/0009 (without RMP)

Applicant: Accord Healthcare S.L.U.
PRAC Rapporteur: Tiphaine Vaillant
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.2. Bortezomib - BORTEZOMIB FRESENIUS KABI (CAP) - EMEA/H/C/005074/R/0010 (without RMP)

Applicant: Fresenius Kabi Deutschland GmbH
PRAC Rapporteur: Amelia Cupelli
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.3. Cannabidiol - EPIDYOLEX (CAP) - EMEA/H/C/004675/R/0031 (with RMP)

Applicant: Jazz Pharmaceuticals Ireland Limited
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.4. Deferasirox - DEFERASIROX MYLAN (CAP) - EMEA/H/C/005014/R/0013 (without RMP)

Applicant: Mylan Pharmaceuticals Limited
PRAC Rapporteur: Tiphaine Vaillant
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.5. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/R/0051 (without RMP)

Applicant: AbbVie Deutschland GmbH & Co. KG
PRAC Rapporteur: Petar Mas
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP
9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States’ safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None
11.2. **Other requests**

None

12. **Organisational, regulatory and methodological matters**

12.1. **Mandate and organisation of the PRAC**

12.1.1. PRAC membership

*Action:* For information

12.1.2. Vote by proxy

None

12.1.3. PRAC working group - Best practice guide on using PRAC plenary time efficiently and effectively – update on the implementation of quantitative goals – Q2 2023

*Action:* For discussion

12.2. **Coordination with EMA Scientific Committees or CMDh-v**

None

12.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

None

12.4. **Cooperation within the EU regulatory network**

12.4.1. Health threats and EMA Emergency Task Force (ETF) activities - update

*Action:* For discussion

12.5. **Cooperation with International Regulators**

12.5.1. International Council for Harmonisation (ICH) M14 Guideline on ‘General principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines’

PRAC lead: Annalisa Capuano

*Action:* For discussion
12.6. **Contacts of PRAC with external parties and interaction with the Interested Parties to the Committee**

None

12.7. **PRAC work plan**

None

12.8. **Planning and reporting**

12.8.1. EU Pharmacovigilance system - quarterly workload measures and performance indicators – Q1 2024 and predictions

**Action:** For discussion

12.8.2. PRAC workload statistics – Q1 2024

**Action:** For discussion

12.9. **Pharmacovigilance audits and inspections**

12.9.1. Pharmacovigilance systems and their quality systems

None

12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. **Periodic safety update reports (PSURs) & Union reference date (EURD) list**

12.10.1. Periodic safety update reports

None

12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Jana Lukačišinová

**Action:** For discussion
12.10.3. **PSURs repository**

None

12.10.4. **Union reference date list – consultation on the draft list**

**Action:** For adoption

12.11. **Signal management**


PRAC lead(s): Martin Huber, Jean-Michel Dogné

**Action:** For discussion

12.12. **Adverse drug reactions reporting and additional reporting**

12.12.1. **Management and reporting of adverse reactions to medicinal products**

None

12.12.2. **Additional monitoring**

None

12.12.3. **List of products under additional monitoring – consultation on the draft list**

**Action:** For adoption

12.13. **EudraVigilance database**

12.13.1. **Activities related to the confirmation of full functionality**

None


12.14.1. **Risk management systems**

None
12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations

None

12.15. Post-authorisation safety studies (PASS)

12.15.1. Post-authorisation Safety Studies – imposed PASS

None

12.15.2. Post-authorisation Safety Studies – non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None
12.20. Impact of pharmacovigilance activities

12.21. Others

12.21.1. Antiepileptic drugs and pregnancy

**Action:** For discussion

13. Any other business

Next meeting on 10-13 June 2024

14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

**EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures**
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: [Referral procedures: human medicines | European Medicines Agency (europa.eu)]

**Signals assessment and prioritisation**
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine’s benefits and risks.

The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.

The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

**Risk Management Plans (RMPs)**
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.

RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

**Assessment of Periodic Safety Update Reports (PSURs)**
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation. PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried
out with this medicine (in the authorised and unauthorised indications).

**Post-authorisation Safety Studies (PASS)**
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

**Product related pharmacovigilance inspections**
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

For a list of acronyms and abbreviations, see:
[List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in Pharmacovigilance Risk Assessment Committee (PRAC)]

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)